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ABSTRACT 
Inflammation is implicated in cancer development, degenerative diseases, 
allergies as well as artherosecelorsis. Dysregulated immune responses lead to chronic 
inflammation and tissue damage. Finding the ways to terminate inflammatory responses 
when no longer needed, demands further investigation.  Herein, we investigated the 
modulation of acute and chronic inflammatory disease models by inducing anti-
inflammatory state. Acute inflammatory model was induced with SEB, an enterotoxin 
produced by a ubiquitous Gram-positive coccus, Staphylococcus aureus (S. aureus), 
which exerts profound toxic effects on the immune system, which leads to the cytokine 
storm and adverse immune response. SEB is the main cause of nosocomial infections, 
acute and fatal respiratory distress and toxic shock syndrome. 
 Regulatory T cells (Tregs) are well characterized for their role in maintaining 
immunological tolerance and immune homeostasis. The immunosuppressive function of 
T regulatory cells correlates with the expression of the forkhead transcription factor 
(Foxp3) in these cells.  However, the precise regulatory mechanisms which govern the 
expression of Foxp3 remain unclear. Herein, for the first time, we uncovered the complex 
interaction of DNA methyltransferase (DNMT) and/or histone deacetylase (HDAC) 
which leads to the reactivation of transcription of Foxp3 mRNA and induction of Tregs. 
More specifically, for the first time, we demonstrated the differential regulation of 
microRNA following administration of an immuno-suppressive environmental 
contaminant, 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in SEB-primed mice.  We
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identified the dual role of miR-31 in induction of Tregs by targeting Foxp3 and CYP-1A. 
Because there is a growing incidence of obesity in the last 25 years which defines  
it as an epidemic condition all over the world, we characterized the mechanism of chronic 
inflammatory disease in Diet-Induced Obesity (DIO) model.  Chronic low-grade, 
systematic inflammation associated with obesity plays a major role in the development of 
various chronic disease states, including type 2 diabetes, metabolic syndrome and 
atherosclerotic cardiovascular disease, which contribute to high rates of mortality and 
morbidity.  
Endocannabinoid system consisting of exogenous and endogenous ligands as well 
as associated receptors, play a major role in diet intake, energy balance, and regulating of 
immune functions. In the current study, we offer a better understanding in the underlying 
mechanism of blockade of cannabinoid CB1 receptor with SR141761A in attenuation of 
DIO phenotype. We revealed that modulation of neuroimmune guidance cue (Netrin-1) 
and its related receptor (Unc5b), via blockade of cannabinoid CB1 receptor, leads to less 
retention of macrophages in adipose tissue, and subsequently causes improvement in 
metabolic functions. In the current study, we have attempted to investigate the impact of 
CB1 receptor antagonist, on gut microbial community in DIO phenotype. Herein, for the 
first time, we identified a rise in Akkermansia muciniphila bacterial community, 
following blockade of CB1 receptor. Interestingly, we uncovered that therapeutic 
properties of SR141716A at microbial level can be attributed to the suppression of 
immunogenic bacteria, Lanchnospiraceace and Erysipelotrichaceae community, in DIO 
phenotype. Furthermore, we found that SR141716A altered microRNA profile in adipose 
tissue macrophages and skewed the balance of adipose tissue macrophages to more anti-
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inflammatory M2 macrophages. These studies provide novel mechanistic information on 
how microbiota and microRNA can be modulated to suppress acute and chronic 
inflammation thereby providing new tools to prevent and treat inflammatory diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
 
 
TABLE OF CONTENTS 
 
Dedication .......................................................................................................................... iii 
Acknowledgements  ........................................................................................................... iv 
Abstract .............................................................................................................................. vi 
List of Tables ..................................................................................................................... xi 
List of Figures ................................................................................................................... xii 
Chapter I: Introduction .........................................................................................................1 
1.1 Staphylococcal Enterotoxin B (SEB)-Induced Acute Inflammation .................1 
1.2 Regulatory T Cells and 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) ............2 
1.3 Diet-Induced Obesity (DIO), Chronic Inflammation .........................................4 
1.4 The Endocannabinoid (EC) System and Immune Regulation ...........................6 
1.5 Microbiota and Immune System………………………………………………9 
1.6 MicroRNA (miR) .............................................................................................11 
1.7 Statement of Hypothesis and Aims ..................................................................12 
Chapter II:  Role of microRNA in Epigenetic Regulation of 2, 3, 7, 8-
Tetrachlorodibenzo-p-dioxin (TCDD)-mediated Induction of Foxp3 in T cells activated 
by Staphylococcal Enterotoxin B…………………………………………………….......14                                                                                                                                                                                            
 
2.1 Introduction ......................................................................................................14 
2.2 Materials and Methods .....................................................................................16 
2.3 Results ..............................................................................................................22 
2.4 Discussion ........................................................................................................30 
 
 
x 
Chapter III:  Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates 
inflammation and diet-induced obesity…………………………………………………..48 
 
3.1 Introduction ......................................................................................................48 
3.2 Materials and Methods .....................................................................................50 
3.3 Results ..............................................................................................................58 
3.4 Discussion ........................................................................................................67 
Chapter IV: Role of microRNA in the regulation of Netrin-1-mediated macrophage 
migration and polarization in adipose tissue through AGAP-2 interaction with UNC5B.94 
 
4.1 Introduction ......................................................................................................94 
4.2 Materials and Methods .....................................................................................97 
4.3 Results ............................................................................................................103 
4.4 Discussion ......................................................................................................110 
 
Chapter V: Summary and Conclusion .............................................................................133 
References ........................................................................................................................136  
 
 
xi 
 
 
 
LIST OF TABLES 
Table 2.1 candidate targets for filtered miRs, along with their seed sequence and 
respective fold change. .......................................................................................................47 
 
Table 3.1 SR141716A treatment improves the impaired CBC in diet-induced obesity 
phenotype ...........................................................................................................................89 
 
Table 3.2 SR141716A treatment improves the impaired metabolic parameters in diet-
induced obesity phenotype. ................................................................................................90 
 
Table 3.3 Composition of Chimeras and Operational Taxonomical Units (OTUs) in 
16srRNA sequencing. ........................................................................................................92 
 
Table 3.4 Primers sequences. The forward and reverse sequences of each primer in the 
current study is provided………………………………………………………….... ……93 
 
Table 4.1 SR141716A causes significant shrinkage of fat mass .....................................117 
 
Table 4.2 Summary of the unique miRs targets M2 polarization in ATMs, following 
SR141716A treatment in DIO phenotype. .......................................................................125 
 
Supplemental Table 4.1 Primers sequences. The forward and reverse sequences of each 
primer used in the study………………………………………………………………...132 
 
Supplemental Table 4.2 Neuronal guidance cue gene expression in HFD+Vehicle vs. 
LFD+Vehicle, and HFD+SR vs. HFD+Vehcile groups. .................................................132 
 
 
 
 
 
 
 
 
 
xii 
 
 
 
LIST OF FIGURES 
Figure 2.1 Treatment with TCDD in vivo reduces percentage and number of SEB-
specific Vβ8 T cells ...........................................................................................................36 
 
Figure 2.2 TCDD induces Tregs and anti-inflammatory cytokines against SEB ............. 38 
 
Figure 2.3 miR expression profile in SEB-injected mice treated with TCDD…………..40 
 
Figure 2.4 In vivo miR expression and target gene expression  
for miR-148a and miR 491………………………………………………………………41 
 
Figure 2.5 miR-34a regulates Histone H3 acetylation in Tregs via HDAC1 ................... 42 
 
Figure 2.6 Foxp3 promoter of TCDD-induced Tregs is transcriptionally active ............. 43 
 
Figure 2.7 miR-31 inhibition leads to induction of Foxp3P3 and CYP1A1 ..................... 45 
 
Supplemental Figure 2.1 TCDD induces AhR signaling by altering miR profile in SEB-
activated T cells. ............................................................................................................... 46 
 
Supplemental Figure 2.2 Schematic of the role microRNA and epigenetic regulators play 
in TCDD induced Foxp3 expression in Tregs. ................................................................. 47 
 
Figure 3.1 SR141716A causes transient reduction in diet intake and persistent weight loss 
as compared with Vehicle-treated DIO control ................................................................ 74 
 
Figure 3.2 SR141716A attenuates local and systematic inflammation in diet-induced 
obesity phenotype ............................................................................................................. 77 
 
Figure 3.3 SR141716A ameliorates metabolic dysfunction in diet-induced obesity 
phenotype .......................................................................................................................... 78 
Figure 3.4 SR141716A restores gut barrier function in diet-induced obesity phenotype.80 
 
Figure 3.5 SR141716A attenuates over-activity of endocannabinoids system in diet-
induced obesity phenotype ................................................................................................ 81 
 
Figure 3.6 SR141716A improves adipose tissue metabolism in diet-induced obesity 
phenotype .......................................................................................................................... 82 
 
 
 
xiii 
Figure 3.7 SR141716A alters gut microbiota in diet-induced obesity phenotype. ........... 85 
 
Figure 3.8 SR141716A treatment changes gut microbiome and its SCFAs metabolites 
which mimics anti-inflammatory status in diet-induced obesity phenotype SR141716A.86 
 
Supplemental Figure 3.1 SR1417161A significantly reduced the interstitial fibrosis of 
adipose tissue in diet-induced obesity phenotype. ............................................................ 87 
 
Supplemental Figure 3.2 SR141716A improves anti-inflammatory Th2 subset and 
Myeloid Derived Suppressive Cells (MDSCs) in diet-induced obesity phenotype. ......... 88 
 
Supplemental Figure 3.3 SR141716A treatment reversed the increase in Free Fatty Acids 
in diet-induced obesity phenotype .................................................................................... 91  
 
Supplemental Figure3.4 SR141716A treatment alters Short Chain Fatty Acids (SCFAs) 
systematically. ................................................................................................................... 93 
 
Figure 4.1SR141716A ameliorates DIO phenotype by inducing weight loss. ............... 116 
 
Figure 4.2 SR141716A intervention treatment ameliorates metabolic dysfunction in DIO 
phenotype. ....................................................................................................................... 119 
 
Figure 4.3 SR141716A treatment in DIO phenotype skew the ATMs balance to less Pro-
inflammatory M1 and more Anti-inflammatory M2 macrophage……………………...121 
 
Figure 4.4 miR-466 family targets M2 polarization in DIO was down-regulated following 
SR141716A, the effect is beyond of SR141716A effect on diet restriction. .................. 124 
 
Figure 4.5 SR141716A treatment changes the miR profile which modifies the adipose 
tissue macrophage retention via negative regulator of neuroimmune guidance cue, 
AGAP-2 .......................................................................................................................... 126 
 
Figure 4.6 Interactions of SR141716A with Netrin-1 and UNC5B ................................ 128 
 
Figure 4.7 SR141716A inhibits macrophage retention in adipose tissue ....................... 129 
 
Supplemental Figure 4.1 Down-regulated miR-466f and miR-466j* in DIO phenotype 
following SR141716A resulted in M2 polarization. ..................................... …………..130 
Supplementary figure 4.2 SR141716A suppressed Netrin-1 secretion from 
BMDM…………………………………………………………………………………131 
 
 
1 
 
 
 
CHAPTER I: INTRODUCTION 
 
1.1 STAPHYLOCOCCAL ENTEROTOXIN B (SEB)-INDUCED ACUTE 
INFLAMMATION 
SEB, is an enterotoxin produced by a ubiquitous Gram-positive coccus, 
Staphylococcus aureus (S. aureus), which has been classified as a super antigen 1that 
exerts profound toxic effects on the immune system, which leads to the cytokine storm 
and adverse immune response 2. SEB is listed as a category B priority agent by Center for 
Disease Control and Prevention due to its usage in a bioterrorist attack 3. SEB is the main 
cause of nosocomial infections, acute and fatal respiratory distress and toxic shock 
syndrome4,5,6.  SEB can activate ~ 20% of T cells by binding both to the non-
polymorphic regions of the Major Histocompatibility Molecules (MHC)II on Antigen 
Presenting Cells (APC), and to the variable region of the β chain of the T cell receptor 
(TCR) such as Vβ8 TCR 7.   
Activation of Mitogen-activated protein kinase (MAPK), extracellular signal 
regulated kinase (ERK),and c-Jun N-terminal kinase (JNK) , and NF-κB pathway in 
triggered T cells leads to massive systematic release of pro-inflammatory cytokines such 
as IL-1β, TNF-α, IFN-γ, IL-2 and IL-4 following exposure to SEB 8.Consequently, the 
circulating leukocytes are attracted to the site of inflammation and cause more damage to 
the tissue 9. Therefore, in order to uncover the immunosuppressive properties of TCDD 
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on robust T cell responses, we designed an acute-inflammatory model by sensitizing in 
vivo with SEB.  
1.2 REGULATORY T CELLS AND 2,3,7,8-TETRACHLORODIBENZO-P-
DIOXIN (TCDD) 
Regulatory T cells (Tregs), formerly known as suppressor T cells, are well 
characterized for their role in maintaining immunological tolerance to the self- antigen 
and immune homeostasis, the essential allies in regulating autoimmunity, cancer, as well 
as inflammatory diseases. Depletion of Tregs is associated with breakdown in immune 
tolerance and sever autoimmunity 10,11,12,13,14,15. Tregs are characterized as small 
proportion of CD4+ T cells (5-10%). Thymus-derived natural Treg (nTreg) and the 
peripherally induced Tregs, are subpopulations of T cells with immunosuppressive 
function. Genetically hypoplasic thymus in DiGeorge syndrome and neonatal 
thymectomy in mice causes defects in Tregs differentiation and peripheral tolerance 16,17. 
Scurfy mutant mice (Foxp3 knock-out) can be rescued from lymphoproliferative 
autoimmune syndrome by bone marrow reconstitution from wild type mice 18,19.   
Cortical epithelial cells in thymus interact with naïve CD4 T cells with their 
MHC-II molecules, and facilitate their differentiation into nTregs 20.  Other stimulatory 
signals from co-stimulatory molecules ( CD40 ligand, and CD28), and cytokines (TNF-α, 
and TGF-β ) are involved in Tregs expansion 21. TGF-β is also known as an essential 
cytokine in mediating peripheral Treg differentiation from the mature conventional T 
cells, and their homeostasis 22. IL-2 is a master regulator of Tregs survival in periphery 
23,24.  
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Numerous surface markers are associated with Tregs such as CD25 (the IL-2 
receptor α-chain), CTL-associated antigen 4 (CTLA4), and glucocorticoid-induced TNF 
receptor (GITR). However, these markers cannot be considered as exclusive markers for 
Tregs.  For example, other immune cells such as activated B cells, T cells and 
macrophages also express surface marker CD25. The forkhead/winged-helix family 
transcription factor (Foxp3), which contributes to development and immunosuppressive 
function of T regulatory cells, is being considered as an exclusive and specific marker for 
Tregs 25,26. However, the precise regulatory mechanisms which govern the stable 
expression of Foxp3 remain unclear. Accessible demethylated locus of Foxp3 gene for 
transcription factors, and other epigenetic regulators such as Histone deacetylases 
(HDAC), phosphorylase and ubiquitin ligase are integral mediator for the stable 
expression of immunosuppressive Tregs 27,28,29,30,31. Tregs can trigger suppression of 
immune responses in direct-contact manner with target cells, Granzyme/perforin 
mediated apoptosis of target cells, or by secreting anti-inflammatory cytokines such as 
IL-10 or TGF-β 32.  
Recently, the role of Aryl hydrocarbon receptor (AhR) in the induction of Foxp3 
in Tregs has generated significant interest 33,34.  AhR was characterized as a ligand-
activated transcription factor involved in xenobiotic metabolism but more recently, it has 
also been shown to play a critical role in the regulation of T cell differentiation, 
specifically induction of Tregs. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a 
ubiquitous environmental contaminant which causes immunosuppression and 
carcinogenesis 35.  TCDD is a potent ligand for AhR because of which it is widely used to 
study the effect of AhR activation in the regulation of immune response.  Induction of 
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functional Tregs and immune-modulatory effect of TCDD in different disease models 
such as Experimental Autoimmune Encephalomyelitis (EAE) and Non-Obese Diabetic 
was well established 36,37. Thus, AhR activation by TCDD-like ligands will provide a 
better understanding in underlying mechanism of Treg induction and their 
immunosuppressive function in immune system activation. 
                            
1.3 DIET-INDUCED OBESITY (DIO), CHRONIC INFLAMMATION 
 The growing incidence of obesity in the last 25 years defines it as an epidemic; 
with estimates upwards of 1.45 billion overweight adults in the world, of which 
approximately 500 million are obese 38. Moreover, a maintenance of childhood obesity at 
16% prevalence from 2006-2010 and a significant increase in obesity prevalence over a 
12-year period in males aged 2-19 years was observed39.  
Chronic low-grade, systematic inflammation associated with obesity plays a 
major role in the development of various chronic disease states, including type 2 diabetes, 
metabolic syndrome and atherosclerotic cardiovascular disease, which contribute to high 
rates of mortality and morbidity 40.   
Stromovascular fraction of adipose tissue is aggregated with immune cells during 
obesity41. In particular, with intense migration of Macrophages (Mɸ) in adipose tissue, 
Adipose Tissue Macrophages (ATMs) have been shown to be integral to the obesity-
triggered inflammation in adipose tissue 42,43,44,  and their recruitment to adipose tissue 
correlates with the production of  pro-inflammatory molecules , including tumor necrosis 
factor-α (TNF-α) 45, interleukin-1β (IL-1β) and IL-6 46,47 that potentiate insulin resistance 
48. Macrophages are phagocytic cells, which show incredible heterogeneity in phenotype 
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and function, as local milieu factors determine their activation state and subsequent 
properties. Mɸs are thought to be activated in two separate pathways becoming polarized 
to M1 or M2 states. With over-nutrition, M1 are said to be “classically activated” mɸs 
induced by LPS and IFNγ that secrete pro-inflammatory cytokines (TNF-α, IL-6, IL-12) 
and generate nitric oxide (NO, a reactive oxygen species) via iNOS activation 49,50. 
However, “alternatively activated” mɸs or M2 that populate lean adipose tissue are 
activated by IL-4 and IL-13, secrete anti-inflammatory cytokines, and have upregulated 
arginase which opposes NO production 51. However, studies have shown that the M1 and 
M2 macrophage phenotypes are not clearly defined, the key signaling molecules such as 
DNA methyltransferase 3b (DNMT3b) and peroxisome proliferator activated receptor-
γ(PPAR-γ) deregulate ATMs polarization, inflammation and insulin insensitivity 50,51 .  
In the current study, we utilized diet-induced obese (DIO) mice as the chronic 
inflammatory disease model. In order to have a better understanding in underlying 
chronic inflammatory mechanism of DIO phenotype and its associated metabolic 
dysfunction, we mainly focused on adipose tissue macrophages (ATMs). For the first 
time we uncovered the regulatory mechanism in induction of anti-inflammatory state in 
adipose tissue by triggering adipose tissue macrophages. The current study may represent 
a novel avenue in treatment of obesity-associated inflammation and metabolic syndrome. 
Outstandingly, our findings can be considered in therapeutic approaches for macrophage-
related inflammatory disease models such as atherosclerotic cardiovascular disease and 
cancer, which contribute to high rates of mortality and morbidity. 
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1.4 THE ENDOCANNABINOID (EC) SYSTEM AND IMMUNE 
REGULATION 
 The onset of medical application of Canabbis sativa or marijuana plant is evident 
from Far Eastern folklore medicine. The Endocannabinoid (EC) system consists of 
classical (CB1, CB2) and non-classical (TRPV1, GPR55, etc) receptors and their 
endogenous and exogenous ligands. In the early 1900’s, British scientists initiated the 
scientific approaches towards cannabis, and made efforts for extracting the principal 
active ingredient of the plant that exert psychoactive effects 54. The preliminary 
experiments of cannabis, in a range of illnesses including cholera, rheumatic diseases, 
delirium tremens and infantile convulsions was conducted to test the possible therapeutic 
properties of the plant. 
Eventually, the natural compounds of cannabis including (–)-Δ9-
tetrahydrocannabinol (THC), with psychotropic activity, and cannabidiol (CBD), non-
psychotropic, were extracted from the plant 55,56. The extraction of the fundamental and 
active ingredient of the plant conveyed attentions to their endogenous binding sites in 
human body. Cannbinoid CB1 receptor was discovered by cloning rhodopsin class	G-
protein-coupled receptors (GPCRs) and experimenting THC for finding its potential 
binding site. Later on, Cannabinoid CB2 receptor was uncovered at Cambridge Medical 
Research Council in UK 54,57. GPCRs are the largest membrane receptors, comprising of 
7 transmembrane helices, and intervening loop N-terminus (an extracellular) and C-
terminus (an intracellular) 58 . 
Ligands for non-classical receptors of Endocannabinoid system such as vanilloid 
(TRPV1) receptor and orphan GPR55 receptors, are comprised of cannabinoid and non-
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cannabinoind (capsaicin) compounds. Vanilloid receptor can also be stimulated by 
voltage, heat, and proton 59,60,61.Therefore, non-classical receptors are not exclusively 
considered  part of endocannabinoid system.  Various organs in human body express 
classical EC receptors (CB1and CB2) with different patterns of intensity. For example, 
central nervous system (CNS) is rich in CB1 receptors. However, CB2 receptors are more 
abundant in periphery and immune system-related cells 62,63. Meanwhile, CB2 receptors 
can also be found in CNS with lesser intensity 63. Macrophages and activated T cells can 
express CB1 receptors as well 64.  Besides CB1/CB2 classical receptors and GPR55, non-
classical receptors of EC, the structures and properties of new EC receptors which 
express on hippocampus and GPR119, remain elusive 65,66. 
 The rhodopsin x-ray crystal structure of CB1 receptors demonstrated the 
existence of hydrophobic binding pocket which requires carbon fatty acid chain with 20-
22 length, saturation of the last five carbons in acyl chain, and the least three double 
bonded carbons (C=C) 67 . Alteration in binding affinity of different ligands and 
cannabinoid receptors is due to the polymorphism in single nucleotide binding site. 
Peptide sequence of CB1 and CB2 receptors revealed 44% similarities between them 
68,69,70,71.   
Investigations for detection of the potential endocannabinoid ligands (endogenous 
ligands), initiated in Raphael Mechoulam's lab led to the discovery of lipid based N-
Arachidonoyl ethanol amine (Anandamide or AEA) in porcine brain in 1992 72,73. The 
plant source of Anadamide was reported in chocolate beans 74. Anadamide is present in 
nearly all tissue and possess anti-inflammatory and orexigenic (appetite stimulant) 
properties 75,76 . 2-Arachidonoylglycerol (2-AG), the second lipid based endogenous 
 
 
8 
ligand of EC system, with the equal binding affinity to both CB1 and CB2 receptors is 
more concentrated in brain than Anadamide 77,78.  2-AG is known as the strong GPCR 
stimulant based on in vitro findings, but the in vivo properties of 2-AG is yet elusive 
because of physiological complexity 79.  Fatty acid amide hydrolysis (FAAH) and 
monoacylglyceride lipase (MAGL), maintain EC levels of AEA and 2-AG respectively 
80,81,82. N-Arachidonoyl dopamine (NADA), Virodhamine (OAE), and 2-Arachidonyl 
glyceryl ether (noladin ether) are the other endogenous ligands in EC systems 79,83,84,85.  
Discovery of EC system was followed by laboratory synthesis of different 
cannabinoids based on the herbal cannabinoid structure. The pioneers in synthetic 
cannabinoid were Roger Adams (1941) and Raphael Mechoulam’s group. The findings of 
the endogenous ligand of EC systems led to the synthesis of new ligands for 
endocannabinoid receptors 86. The synthetic ligands were structured in agonist or 
antagonist (inverse agonist) modes for specific endocannabinoid receptors 87.  
SR141716A also known as Rimonabant, Acomplia , and Zimulti was the first 
selective CB1 receptor blocker (inverse agonist) to be approved for use as an anti-obesity 
drug 88. The therapeutic effect of Rimonabant is not restricted to its anorectic properties, 
secession of smoking and addiction behaviors, improvement of short term memory, 
improvement of human sperms motility and viability, as well as inversing the 
psychoactive and cardiovascular effect of THC are considered as Rimonabant therapeutic 
applications 89,90,91,92,93.  
Endocannabinoid system possess Neuro-protective and immune-modulatory 
effects. Immuno-modulatory effect of endocannabinoid and cannabinoid systems, is 
reliant on the intensities of cannabinoid receptor expression in blood immune cells (with 
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the following rank order: B cells > NK cells > monocytes/macrophages > 
polymorphonuclear neutrophils > CD8 lymphocytes > CD4 lymphocytes) 94  . Activation 
of endocannabinoid system in experimental autoimmune encephalomyelitis (EAE), an 
animal model of multiple sclerosis and MS patient (High level of Anandamide) was 
recognized. The intervention treatment with anandamide uptake inhibitor UCM707 can 
significantly ameliorates the pathological score of the disease 95,96,97 .  Anti-tumor activity 
of Anadamide on Molt-4 human tumor cells, and murine EL-4 tumor T cells, was 
established by demonstrating its ability to trigger significant level of apoptosis 98. Thus, 
management of endocannabinoids system may establish an innovative treatment modality 
against inflammatory disorders. 
                                        
                                       
1.5 MICROBIOTA AND IMMUNE SYSTEM 
Microbial community of gut is consisting of symbionts (beneficial), neutral 
(commensals) as well as detrimental (pathobionts) microorganisms. The homeostasis of 
these essential allies can modulate the host health and function.   
Age, genetic, physiology, diet, environment are the main factors impacting gut 
microbiota 99. Gut community becomes more stable, diverse, and highly complex by age 
100. Diet is the most potent manipulator of the gut microbial compositions. Previous 
studies have shown that both long term diet habit as well as short term changes in diet 
can lead to shift in gut microbiota 101,102. Dietary pattern of more protein consumption is 
associated with more prevalence of Bacteroides versus more carbohydrates in diet is 
correlated with remarked gut Prevotella entrotype. Short term changes in diet also can 
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introduce rapid changes in the abundancee of gut microbiome 103. Previous studies 
demonstrate that antibiotic treatment leads to disturbance of gut community and the 
repeated administration of antibiotic leads to profound and more permanent alteration in 
gut community 104. The presence, absence and variations in particular genes also correlate 
with abundances of specific genera of gut microorganism. Break-down of tolerance to 
intestinal microbial community in IL-10 deficient mice, resulted in impulsive 
enterocolitis, adenocarcinoma, and subsequently spontaneous development of 
inflammatory bowel syndrome 105.  
Hormone level, metabolism, immune system function and other physiological 
factors can also alter intestinal microbiota 106,107,108,109,110. Dysbiosis of gut microbial 
community is associated with chronic inflammatory diseases including ulcerative colitis, 
diet-induced obesity and metabolic syndrome. Gut immune system determines 
colonization of microbial community in gut and contributes to the interaction of host-
microbiome 111.  Dysregulation in innate (antibacterial peptide of Paneth cells and 
enterocytes) and adoptive (IgA production in mucosal associated lymphoid tissue) 
immune system function of gut also caused by the damage in gut barrier, leads to collapse 
in homeostatic state of intestinal host-microorganisms 112,113,114. 
Thus, the potential therapeutic approaches to alter microbiota to treat a wide range 
of diseases, ranging from metabolic disorders (e.g. obesity and type 2 diabetes) to 
autoimmune diseases (such as inflammatory bowel disease and colitis), cancer, 
neurodevelopmental disorders (e.g. autism), and even allergies (Food poising, asthma), 
remains an exciting possibility that remains to be further explored. Taken together, 
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studies on gut microbiota, its manipulation, and fecal transplantation is considered as a 
potential therapeutic strategy for many disorders.  
 
                                      1.6 MICRORNA (MIR) 
MicroRNAs (miRNAs) are a class of small non-coding RNAs (~18-22 
nucleotides) with highly conserved RNA sequences 115. miRNAs are capable of 
regulating gene expression at post-transcriptional and post-translational level. The first 
miRNA discovered in C.elegans in 1993, was named lin4 116. Several miRNAs have been 
involved in regulating innate and adoptive immune systems. Dysregulated miRNA 
profile in several disorders including cancer, inflammatory disease, and autoimmune 
illness has been reported 115. For instance, two different miRNA (miR-155 and miR-182) 
were implicated in SEB-induced Acute Lung Injury (ALI) 117,118.  
miRNAs which are known as the negative regulator of gene expression, can bind 
to the complementary sequences of the 3′ untranslated region (3′ UTR) of their target 
genes, and lead to mRNA degradation or translational cessation 119,120.  
Different algorithms (miRmap, TargetScan, and miRwalk, etc) for target 
prediction are available. Ingenuity systems such as Ingenuity Pathway Analysis (Qiagen, 
Valencia, CA) tools and its modules, are a powerful system in prediction of differentially 
altered miRNA, their down-stream and up-stream effects, and top affected canonical 
pathways. Importing the differentially expressed genes into Cytoscape (ClueGo module) 
or other gene ontology software help predict the most implicated pathways.  
In the current study, we investigated the role of the miRNA in amelioration of 
acute (SEB-primed mice) or chronic (Diet-Induced Obesity, DIO) disease models. We 
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identified the unique miRNAs which are the key regulators in modulating the immune 
responses and maintaining the immune homeostasis during the inflammatory disorders.  
 
                          1.7 STATEMENT OF HYPOTHESIS AND AIMS 
Because of the growing rise in autoimmunity and inflammatory disorders that are 
causing public health crisis, further investigation is critically needed to understand the 
mechanisms of pathogenesis as well as finding novel therapeutic approaches such as new 
non-toxic immunosuppressive drugs and other biologicals.  Furthermore, chronic 
inflammation is implicated in a large number of immuno-pathological disorders including 
cardiovascular, neurodegenerative, cancer, diabetes, and metabolic disorders.  Thus, 
understanding the underlying basic mechanisms of acute and chronic inflammation will 
open up new avenues for better targeted therapeutics for inflammatory disorders and their 
complications.  
In the current study, we tested the central hypothesis that inflammation is 
regulated by complex interactions between epigenome and microbiome.  Thus, agents 
that alter microRNA in immune cells and gut microbiota, can be used effectively to 
attenuate acute and chronic inflammation.    
To test this hypothesis, in the first part of this study, we investigated the 
molecular mechanism of induction of immunosuppressive regulatory T cells(Tregs), after 
AhR activation with TCDD.  Our data uncovered novel regulatory pathways mediated by 
microRNA that are induced following AhR activation that trigger inducible regulatory T 
cells, and attenuate acute inflammation.   
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In the second part of our study, we developed diet-induced obesity (DIO) 
phenotype as the model to study chronic inflammation.  We targeted the endocannabinoid 
system in DIO by blocking the cannabinoid receptors and investigated its effect on  
miRNA profile and gut microbiota.  Our data identified novel miRNA that targeted pro-
inflammatory M1 macrophages and promoted their differentiation into anti-inflammatory 
M2 macrophages.  Also, such a treatment to block cannabinoid receptors led to altered 
microbiota that promoted anti-inflammatory phenotype.  Finally, we discovered a novel 
interaction of with neuroimmune guidance cue receptors and their related ligands which 
regulate macrophages chemotaxis, thereby attenuating inflammation and DIO phenotype. 
Together, the current study has identified how targeting AhR and Cannabinoid receptors 
leads to alterations in microRNA and microbiota profiles, which in turn attenuate 
inflammation.   These studies form the basis for developing novel therapeutic regimen to 
treat inflammatory diseases. 
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CHAPTER II:  ROLE OF MICRORNA IN EPIGENETIC REGULATION OF 2, 3, 
7, 8-TETRACHLORODIBENZO-P-DIOXIN (TCDD)-MEDIATED INDUCTION 
OF FOXP3 IN T CELLS ACTIVATED BY STAPHYLOCOCCAL 
ENTEROTOXIN B 
                                           
2.1 INTRODUCTION 
 Regulatory T cells (Tregs) are well characterized for their role in maintaining 
immunological tolerance and immune homeostasis 121,122. The immunosuppressive 
function of T regulatory cells correlates with the expression of the forkhead transcription 
factor (Foxp3) in them 123,124 , however, the precise regulatory mechanisms which govern 
the expression of Foxp3 remain unclear. Recently, the role of Aryl hydrocarbon receptor 
(AhR) in the induction of Foxp3 in Tregs has generated significant interest 125,126.  AhR 
was characterized as a ligand-activated transcription factor involved in xenobiotic 
metabolism but more recently, it has also been shown to play a critical role in the 
regulation of  T cell differentiation, specifically induction of Tregs. 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous environmental contaminant which 
causes immunosuppression and carcinogenesis 127.  TCDD is a potent ligand for AhR 
because of which it is widely used to study the effect of AhR activation in the regulation 
of immune response.    
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Epigenetic modifications such as DNA methylation of regulatory sequences, 
histone modifications and post-transcriptional and post-translational repression by 
microRNA are key players which direct the overall immune response 128,129.  Considering 
that AhR activation regulates Treg differentiation, and our previous studies 
demonstrating the ability of TCDD to modulate miR profile as well as cause epigenetic 
changes in immune cells, we were interested in knowing if there is any cross talk between 
these pathways that impact Treg differentiation during antigen exposure.  It is known that 
the majority regulation of gene expression is mediated by various transcriptional factors 
via binding to their recognition sequences in the upstream of enhancer region of gene.  
Regulation of methylation of CpG dinucleotides in the gene regulatory region and 
acetylation of histones in nucleosome structure  modifies the transcription pattern of 
genes by modulating the access of the transcription factors to their recognition sequences. 
Previously, it has been shown that TCR activation leads to the accumulation of Methyl-
binding proteins MBD, MeCP1, MeCP2, and DNA methyltransferases (DNMTs) in 
Foxp3 promoter region, which results in repression of Foxp3 transcription 130,131. 
Treatment of activated T cells with DNA methyltransferase (DNMT) and/or histone 
deacetylase (HDAC) inhibitors leads to the reactivation of transcription of Foxp3 mRNA  
and induction of Tregs 132,133. Suppression of DNA methyltransferases at the regulatory 
regions of the gene is followed by less recruitment of histone deacetylases (HDACs)22 . 
HDACs enzymes catalyze the removal of the acetyl groups from the lysine residue in 
histones and thus results in closed chromatin configuration, which limits the access of the 
transcription factors to their recognition sequences 134,135.  
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In order to have a broader view of epigenetic mechanism regulating gene 
expression with TCDD treatment, we performed high throughput analysis of microRNAs 
which identified several pathways, including DNA methylation, Histone acetylation, Aryl 
hydrocarbon receptor (AhR) signaling, and differentiation of Tregs.  Furthermore, our 
data demonstrated that TCDD influences the accessibility of Foxp3 transcription factor 
binding sequences by triggering DNMTs and HDACs in T cells activated by SEB.   
  
                               
2.2 MATERIALS AND METHODS 
Animals- 
Female C57BL/6 mice (aged 6-8 weeks) were purchased from the Jackson 
laboratory (Bar Harbor, ME). Foxp3/GFP knock-in mice, encoding a GFP-Foxp3 fusion 
protein were purchased from Jackson laboratory (Bar Harbor, ME). All mice were housed 
at the (American Association for the Accreditation of Laboratory Animal Care ( 
AAALAC)-accredited animal facility at the University of South Carolina, School of 
Medicine (Columbia, SC).  All procedures were performed according to NIH guidelines 
under protocols approved by the Institutional Animal Care and Use Committee. 
 
Effects of TCDD on mice primed with SEB in vivo- 
To determine the effect of TCDD on T cell response to SEB, mice were injected 
with SEB, in sterile phosphate-buffered saline (PBS), or PBS alone as a vehicle, into hind 
footpads of mice (10ug/footpad) once, as previously described (24200994) SEB was 
obtained from Toxin Technologies (Sarasota, FL).  TCDD, kindly provided by Dr. Steve 
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Safe (Texas A & M Health Science Center, Collage Station, Texas), was administered 
immediately after SEB, intraperitonally (ip) at 10µg/kg in a total volume of 100ul in 
vehicle (corn oil) as previously described 136 .The draining popliteal lymph nodes (PLN) 
were excised from mice and made into single-cell suspensions by a tissue homogenizer. 
Cells were subjected to red blood cell lysis, counted, and stained with antibodies 
purchased from Biolegend (San Diego, CA) against CD3, Vβ8, Foxp3 and CD4, and 
analyzed by Beckman Coulter FC500 flow cytometer  (Indianapolis, IN) 
 
Measurement of cytokines from collected serum- 
Cytokines levels were analyzed in the serum using enzyme-linked immunosorbent 
assay (ELISA) kits for interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), 
transforming growth factor-β (TGF-β) interleukin-6 (IL-6), and IL-10 purchased from 
Biolegend (San Diego, CA), as described 137.  All ELISAs were performed as per the 
manufacturer’s instructions. 
 
Total RNA isolation- 
Total RNA (including small RNAs) was isolated from selected CD4+ cells 
(EasySep TM PE Positive Selection kit, Stem Cell Signaling, Vancouver, BC) from PLNs 
using the miRNeasy kit from Qiagen (Valencia, CA) by following the manufacturer's 
instructions. The purity and concentration of the RNA was confirmed 
spectrophotometrically with Nanodrop (Thermo Scientific, Waltham, MA) 
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miRs expression profiling and analysis- 
The expression profile of miRs was assessed in the PLN cells by Affymetrix 
GeneChip miRNA 1.0 array platform 138. The array contains 609 murine-specific probes 
from Sanger miRBase . Total RNA was labeled with FlashTag biotin HSR hybridization 
(Genisphere, Hatfield, PA) as described in manufacturer's instructions (Affymetrix, Santa 
Clara, CA). Correlation of the hybridization signal intensities of all the expressed 
miRNAs were log transformed and visualized in the form of a heatmap.  Ward’s method 
was assessed for hierarchical clustering of differentially expressed miRs. miRNA QC 
Tool (Affymetrix Inc), a software for data summarization, Log2 transformation, 
normalization and quality control, was used as described previously 139  . 
 
Purification and analysis of mouse T regulatory Cells (Tregs) and T cells- 
Tregs were sorted from Foxp3/GFP knock-in mice. The LN cells were sorted for 
GFP using flow cytometry to isolate Foxp3+  Tregs.   regulatory cells by sorting with. In 
some experiments, CD4+ T cells were purified using EasySep TM PE Positive Selection 
kit (Stem Cell Signaling, Vancouver, BC) and CD4 PE antibody (BioLegend, San Diego, 
CA).  
 
Chromatin immunoprecipitation (ChIP) assay-  
ChIP assay was performed using the ChIP kit (Cell Signaling, Danvers, MA), as 
described 140. The DNA which was immuno-precipitated was amplified by qRT-PCR. 
Antibodies against the molecules used were as follows:  DNMT3a, DNMT3b, DNMT1 
and MeCP1 from NovusBio (Littleton,CO); KLF10 and AcH3 from Active Motif 
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(Carlsbad, CA); Sp1 from Abcam (Cambridge, MA); H3K9 from Cell Signaling 
(Danvers, MA). The primers sequences used for the upstream Foxp3 enhancer CpG site 
and Foxp3 proximal promoter were the same as previously described 141. 
UpstreamFoxp3 enhancer CpG site were 5#-GCGGAGAGGGATCGGGAAA-3# 
(forward) and 5#-ATGAGGAAGACGATGGCGAGGAT-3# (reverse), and the primers 
for the Foxp3 proximal promoter were 5#-CCTTGGCAACATGATGGTGGTGAT-3# 
(forward) and 5#-AAGAAGGGATCAGAAGCCTGCCAT-3# (reverse). 
 
Bioinformatics analysis- 
The differentially expressed miRNA target genes were assessed by three of the 
leading miRNA target prediction algorithms: miRwalk (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/), microRNA.org 
(http://www.microrna.org/microrna/home.do) and TargetScan 
(http://www.targetscan.org/).  
To carry out an enrichment analysis of predicted target genes of miRs in 
biological pathways, we used, Ingenuity Pathway analysis (IPA), (Mountain View, CA, 
USA.).  IPA predicts the top affected Canonical Pathways, causal connections between 
differentially altered miRs and their target genes, downstream effect along with their 
upstream regulators. The Molecular Activity Predictor (MAP) feature of IPA was 
performed to predict the downstream effect of the differentially expressed miRs which 
were overlaid to the dataset including miRs probes, fold changes and the p Values. 
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qReal Time PCR(qRT-PCR)-  
Expression of mature miRNAs and target genes was determined by quantitative 
qRT-PCR. Total RNA was converted to cDNA using the miScript cDNA synthesis kit 
(Qiagen, Valencia, CA) according to the manufacturer's instructions. For miRNA 
validation, the miScript SYBR green PCR kit (Qiagen, Valencia, CA) was used, and fold 
change of miRNA was determined by using the 2−ΔΔCT method. Snord96a was used as 
small RNA endogenous control. For mRNA validation, an SSO advanced SYBR green 
PCR kit from Bio-Rad (Hercules, CA) was used according to the manufacturer's 
instructions, and GAPDH was used as an endogenous control. The following primers 
were used:  GAPDH forward (F) (5′-AATGGATTTGGACGCATTGGT -3′) and reverse 
(R) (5′-TTTGCACTGGTACGTGTTGAT -3′); Foxp3 F (5′-
CACCTATGCCACCCTTATCCG-3′) and R (5′-CATGCGAGTAAACCAATGGTAGA-
3′) and CYP1A1 F (5′-CAATGAGTTTGGGGAGGTTACTG-3′) and R (5′-
CCCTTCTCAAATGTCCTGTAGTG-3′), KLF10 F (5′-
GTGACCGTCGGTTTATGAGGA-3′), and R (5′-AGCTTCTTGGCTGATAGGTGG-
3′), Sp1 F (5′-ATCACTATGGTTGCGATGGACT-3′), and R (5′-
GCCGATCCAGTTACGGGAG-3′), DNMT1 F (5′- 
AAGAATGGTGTTGTCTACCGAC-3′), and R (5′-CATCCAGGTTGCTCCCCTTG-3′), 
DNMT3A F (5′-GAGGGAACTGAGACCCCAC-3′), and R (5′-
CTGGAAGGTGAGTCTTGGCA-3′), DNMT3B F (5′-
AGCGGGTATGAGGAGTGCAT-3′), and R (5′-GGGAGCATCCTTCGTGTCTG-3′), 
Mecp2 F (5′- ATGGTAGCTGGGATGTTAGGG-3′), and R (5′- 
TGAGCTTTCTGATGTTTCTGCTT-3′) 
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Transfection with miR-31 mimic, inhibitor, Foxp3 target gene protector and 
CYP1A1 target gene protector- 
  Lymph nodes from naive C57BL/6 mice were harvested and cultured in 10 ml of 
complete medium at 37°C and 5% CO2. Complete medium was comprised of RPMI 
1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal 
bovine serum (FBS), 10 mM L-glutamine, 10 mM HEPES, 50 µM β-mercaptoethanol, 
and10 U/mL Penicillin/streptomycin. Cells were seeded at 4 × 105 cells in 24-well plates 
and transfected with either 40 nM synthetic mmu-miR-31-5p miScript miRNA mimic 
(AGGCAAGAUGCUGGCAUAGCUG) or AllStar negative-control small interfering 
RNA (siRNA). For inhibiting the miR-31, cells were treated with 100 nM anti-mmu-
miR-31-5p miScript miRNA inhibitor (AGGCAAGAUGCUGGCAUAGCUG) or 
miScript AllStar negative control for 24 h using HiperFect transfection reagent (Qiagen, 
Valencia, CA) according to the manufacturer's instructions.  To assess a reliable 
verification of miRNA-targeted genes, the transfection of the cells with miScript target 
protector for Foxp3 gene and CYP1A1 genes was performed. Target Protectors was used 
provide evidence that a gene is regulated by a particular miRNA. Foxp3miScript target 
protector was designed as: 
CTGCAATTCTGGAGACAGCA 
AGAATACAAGGCTTGCACCT 
This target protector was aimed to detect several transcripts of the same gene 
(Foxp3): NM_001199348, NM_001199347, NM_054039 
CYP1A1 miScript target protector was designed as: 
TTCTGGCACAGAGGTGCTCT 
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TGCCACCTGCTGAGGCTAAA 
This target protector was aimed to detect several transcripts of the same gene (Cyp1a1): 
NM_001136059, NM_009992. 
In these experiments, All-star negative control and negative control miScript Target 
protector were used.   
 
Statistical Analysis- 
For the in vivo mouse experiments, 5or 4 mice were used per experimental group, 
unless otherwise specified. In vitro experiments were performed in triplicate.  For 
statistical differences, one-way ANOVA was calculated for each experiment.  Tukey’s 
post-hoc test was performed to analyze differences between groups.  A p value of ≤ 0.05 
was considered statistically significant. 
 
 
2.3 RESULTS 
 
TCDD decreases induction of SEB-driven Vβ8+ T cells and pro-inflammatory 
cytokines. 
SEB is known to selectively trigger a strong Vβ8+ T cell response and the 
cytokines storm. We investigated the effect of TCDD on SEB-induced inflammatory 
response in vivo. Our lab had previously shown that a single dose of 10µg/kg of TCDD 
was able to markedly decrease lymphocyte infiltration into colon lumen in the mouse 
model of colitis127.  Thus, to investigate the efficacy of TCDD in amelioration of SEB-
induced inflammation, we used the same dose.  We treated mice with ip injections of 
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TCDD at the same time as the administration of SEB into footpads. In order to determine 
if TCDD could suppress SEB-induced T cell proliferation in draining PLN, we analyzed 
the cells on day 3, the peak of the response 131.  Because SEB activates Vβ8 TCR+ T cells 
142, we examined their percentage and absolute cell numbers by staining the cells for CD3 
and Vβ8 and analyzing them by flow cytometry.  The data showed that in SEB+TCDD 
treated mice, there was marked decrease in the percentages of Vβ8+ T cells (8.3%) when 
compared SEB+Vehicle treated mice (14.1%) (Fig 2.1A).  TCDD treatment also caused a 
significant decrease in the total cell numbers (Fig 2.1B). 
Because SEB triggers cytokine storm143, we next investigate the effect of TCDD 
on pro-inflammatory cytokine production both in the serum and in the draining lymph 
node (LN) following SEB administration.  The data showed that TCDD treatment caused 
significant decrease in inflammatory cytokines, including IFN-γ, TNF-α, and IL-6 both in 
the serum (Fig 2.1C) as well as in the PLN culture supernatants (Fig 2.1 D), when 
compared to controls.  
 
TCDD induces T regulatory cells and anti-inflammatory cytokines. 
We next determined whether TCDD induces, Tregs in popliteal LNs of SEB 
primed mice.  We noted a significant increase in the frequency of Tregs in the popliteal 
lymph node in SEB+TCDD group when compared to SEB+vehicle group (Fig 2.2A).  
Also, TCDD treatment induced significant increase in anti-inflammatory cytokines, 
including IL-10, TGF-β (Fig 2.2B).  
Next, we determined if TCDD would enhance the induction of Tregs that were 
antigen (SEB)-specific.  To test this, we used Foxp3/GFP knock-in mice, which were 
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immunized with SEB and treated with vehicle or TCDD.  Three days later, the level of 
expression of Foxp3 within Vβ8+  T cells was analyzed by flow cytometry. Interestingly, 
TCDD caused significant induction of Foxp3 + Vβ8+ T cells, thereby suggesting that 
TCDD does induce antigen-specific T cells (Fig 2.2C) 
To confirm that the TCDD-treated Tregs were indeed able to suppress SEB-
activated T cell proliferation and cytokine production, we performed cell-mixing 
experiments.  Tregs were isolated from the Foxp3/GFP knock-in mice and treated with 
100 nM TCDD as previously described 127.  Cell-mixing experiments were performed by 
co-culturing Tregs and SEB-activated LN cells. Our results demonstrated that TCDD-
derived Tregs suppressed the SEB-activated T cell proliferation in a dose-related manner 
(Fig 2.2D).  In these co-culture supernatants, when we measured cytokines, we observed 
significant suppression of the pro-inflammatory cytokines (TNF-α, IFNγ, and IL-6) and 
induction of anti-inflammatory cytokines (Fig 2.2E) 
 
 
TCDD administration profoundly changes the miR profile. 
To investigate the role of miRs in TCDD-mediated decrease in anti-SEB T cell 
response differential expression of miRs was assessed using Affymetrix GeneChip® 
array of SEB-activated T cells, following vehicle or TCDD treatment. Cluster analysis of 
609 miRs was analyzed by unsupervised hierarchical clustering and visualized in the 
form of dendrogram (Fig 2.3A).  SEB+TCDD group showed distinct miR expression 
profile when compared to SEB+vehicle treated group.   We performed further analysis 
and identified 37 miRs that were significantly upregulated and 51 miRs that were 
significantly downregulated in SEB+TCDD groups when compared to SEB+vehicle 
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treatment group (Fig 2.3B). Next, we used Ingenuity Pathway (IPA) software application 
to identify the candidate targets for filtered miRs, which are shown in (Table 1), along 
with their seed sequence and respective fold change. A comprehensive network showing 
the interaction of the miRs and their target genes was generated by IPA (Fig 2.3C).   
TCDD-mediated alterations in the expression of miRs were linked to many pathways 
including AhR signaling (ARNT), apoptosis (Fas, FasL, caspases, BCL2), epigenetic 
(DNMTs and HDACs), and Tregs (Foxp3).   
 
Over-expression of miR-148a and miR-491 upon TCDD administration, ameliorates 
demethylation of Foxp3 promoter regions. 
The critical role of DNA Methyltransferases (DNMTs) within regulatory regions 
of Foxp3 was stressed by studies showing that conditional deletion of DNMT1in mice 
resulted in lethal autoimmunity, which can be reversed by the exogenous transfer of 
Tregs 144.  Interestingly, in the affymetrix microarray, we noticed that miR-148a and 
miR-491 were up-regulated upon TCDD exposure.  We validated these findings with 
qRT-PCR, in which we showed that miR-148a and miR-491 were up-regulated in 
SEB+TCDD treated groups when compared to SEB+vehicle controls (Fig 2.4 A, and 2.4 
B).  We determined by Ingenuity Pathway Analysis that miR 148a and miR-491 target 
DNA methyltransferase, DNMT1, DNMT3a, and DNMT3b by binding to their 3’UTRs 
with significant mirSVR scores. Our results demonstrated the inverse correlation between 
miR-148a, miR-491 with DNMTs, in which over expression of miR-148a, miR-491 
following TCDD treatment in activated T cells resulted in significant reduction in 
DNMT3a, DNMT3b and DNMT1 (Fig 2.4C, 2.4D, and 2.4E).  
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In order to investigate the interaction of DNMTs with Foxp3 promoter region, 
which contains the recognition binding sequences for transcription factors, we performed 
CHIP assays for DNMTs.  We used purified Tregs from Foxp3/GFP knock-in mice as 
described in Methods.  Our results demonstrated that Tregs from SEB+TCDD mice 
exhibited significant decrease in DNMT1 and DNMT3b binding to Foxp3 promoter CpG 
island when compared with SEB+Vehicle group (Fig 2.4 F, 2.4G).  Whereas, there was 
no significant difference in DNMT3a and MeCP2 binding to Foxp3 promoter (Fig 2.4 H, 
2.4 I). These data suggested that TCDD may inhibit DNA methyltransferase (DNMTs) in 
activated T cells, which may result from up-regulation of miR-491 and miR-148a. 
 
miR-34a regulates Histone H3 acetylation in Tregs via HDAC1. 
Previous studies from our laboratory demonstrated the involvement of HDAC-I 
family in SEB-activated T cells, in which HDAC-I was highly up-regulated in T cells 
upon SEB activation when compared to naïve T cells 131 .  Data obtained from high 
throughput analysis, showed significant over expression of miR-34a (> 2.2) in 
TCDD+SEB group compared with Vehicle+SEB. Furthermore, we validated these 
findings with qRT-PCR, in which miR-34a was markedly up-regulated in TCDD+SEB 
group compared to Vehicle+SEB (Fig 2.5A). HDAC1, a target gene of miR-34a was 
significantly suppressed upon TCDD administration in SEB-activated T cells (Fig 2.5B). 
Next, we tested whether the decreased HDAC-1 triggers acetylation of H3.  As before, 
we isolated Tregs, from Foxp3/GFP knock-in mice using the two groups: SEB+TCDD 
and SEB+vehicle.  Chip assay was conducted for acetylation of histone 3 (AcH3) 
upstream of Foxp3 enhancer region. Our data demonstrated that Foxp3 regulatory region 
was significantly more acetylated in TCDD+SEB group compared with Vehicle+SEB 
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group (Fig 2.5C). Chip assay was performed for acetylation of H3K9 in Foxp3 promoter 
region and our data showed higher acetylation of H3K9 in Foxp3 regulatory region (Fig 
2.5D). Taken together, our data suggested that decreased HDAC expression in SEB 
activated T cells which were treated with TCDD, correlated with increased acetylation of 
H3K9. The promoter region of actively transcribed gene is often acetylated at histone H3 
lysine 9. Therefore; TCDD causes Tregs induction through the important epigenetic 
modification (HDAC/H3K9). 
 
TCDD regulates the active binding of Sp1/KLF10 in Treg promoter via epigenetic 
mechanism. 
Active role of the transcription factor Sp1 (specificity protein 1) in protection of 
CpG islands from de novo methylation is well established 145,146,147.  KLF10, a member of 
the Krüppel-like family of transcription factors, binds to Sp-1-GC rich DNA sequences 
and regulates the transcription of a number of genes 148.  In the present study, we 
therefore evaluated the expression level of KLF10 and Sp1 following TCDD 
administration in SEB-activated T cell with real time qRT-PCR, and the data showed that 
they were markedly up-regulated compared with SEB-activated T cell (Fig 2.6A, 2.6B).  
We then studied the predicted miRs regulators of Sp1 and KLF10 by Ingenuity Pathway 
Analysis (IPA) software.  miR-31 is predicted to target Sp1 expression with mirSVR 
score: -0.1127 , and PhastCons score: 0.5983, while miR-26b is predicted to regulate 
KLF10 expression with mirSVR score: -0.6935, and PhastCons score:0.6217. 
Furthermore, we noticed that in affymetrix microarray, miR-31 (Fold change: -
1.60) and miR-26b (Fold change: -1.80) were down-regulated in SEB+TCDD group 
compared with SEB+vehicle group. We confirmed these findings by conducting qRT-
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PCR, in which miR-31 was found to be down-regulated ~10 times and miR-26b was 
down-regulated ~3 times compared to vehicle treated group (Fig 2.6C, 2.6D).  Next, Chip 
assay was used to show interaction of KLF10/Sp1 with upstream of Foxp3 enhancer 
region, using Tregs isolated from Foxp3/GFP knock-in mice, as before. Our data 
demonstrated that upon TCDD treatment in SEB-activated T cells there was more 
interaction of KLF10/Sp1 with Foxp3 promoter region compared to SEB+vehicle-
activated T cells (Fig 2.6E. 2.6F), which led to the higher induction of Foxp3. 
 
Dual role of miR-31 in TCDD-mediated upregulation of CYP1A1 and Foxp3 in 
activated T cells. 
We we explored the putative target genes of miR-31 by using the comprehensive 
pipeline of ten different reliable algorithms miRWalk 2.0 149,150, interestingly, we noted 
that  Foxp3 was also identified as the highly predicted target gene for miR-31 ( p <0.05) 
using at least 5 different databases (miRwalk2.0, miRTarBase, miRecords, and TarBase 
7.0, and PICTAR 2.0) We next  utilized the miR functional analysis to investigate the 
effect of decreased expression of miR-31 in induction of functional and suppressive 
Tregs. Efficient inhibition of miR-31 activity in T cells was achieved by transfecting the 
SEB-activated T cells with customized inhibitor for miR-31.  The data showed that the 
expression level of Foxp3 was significantly higher in transfected T cells with miR-31 
inhibitor when compared to the mock (Fig 2.7A). Finally, we tested whether miR-31 
regulates the expression of Foxp3 by directly targeting its 3’ untranslated region or 
targets any negative or positive intermediate regulator of Foxp3 gene. For this purpose, 
we transfected SEB-activated T cells with miR-31 mimic and specific custom-designed 
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Foxp3 target protector. Our results demonstrated that while miR-31 mimic suppressed the 
expression level of Foxp3, co-transfection with miR-31mimic and Foxp3 target protector, 
resulted in higher expression of Foxp3 when compared to the mimic (Fig 2.7B, 2.7 C). 
Taken together, these data suggested Foxp3 as the direct target gene for miR-31.  
Interestingly, using 4 different databases (miRWalk 2.0, microrna.org,miRBase, 
and Target Scan), we also identified CYP1A1 as the highly predicted target gene for 
miR-31. Transcription of  CYP1A1 was markedly suppressed  in transfected SEB-
activated T cells with synthetic mimic for miR-31 , while co-transfection of SEB-
activated T cells with mimic-31 and CYP1A1 target protector, rescued CYP1A1 from 
suppressive function of mir-31 mimic (Fig 2.7D). These data demonstrated that miR-31 
can also directly regulate the transcription of CYP1A1.   
 
TCDD induces AhR signaling by altering miR profile in SEB-activated T cells. 
In the data assessed from affymetrix microarray, we also distinguished a group of 
18 miRs, that were implicated in AhR signaling pathway. Using IPA software, we 
overlaid the AhR signaling canonical pathway with differentially expressed miRs and 
explored for meaningful paths by applying the Molecular Activity Predictor (MAP) 
feature to have an overview of the downstream effect of the differentially expressed miRs 
(Fig 2.8A). Among these miRs, we focused on the differential expression of miR-455, 
and miR-351 using qRT-PCR, and found that both miRs were significantly down-
regulated in SEB+TCDD group compared with SEB+vehicle (Fig 2.8A, 2.8B).  Also, 
ARNT, the target gene for miR-455, along with the CYP-1A1, the target gene for miR-
351, were significantly up-regulated in SEB activated T cells upon TCDD treatment (Fig 
 
 
30 
2.8C, 2.8D), when compared to controls. These data demonstrated that TCDD–mediated 
differential expression of miRs can also play a critical role in AhR-signaling pathway.   
 
                                                2.4 DISCUSSION 
 
In the current study we investigated the effect of 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD), an environmental contaminant, on T cell response to Staphylococcal 
Enterotoxin B (SEB), which is classified as the super antigen. In the mouse, SEB 
activates T cells that express the TCR, Vβ8.  Thus, by studying Vβ8+T cells, one can 
investigate the direct effect of TCDD on antigen-specific T cells. In the current study we 
observed that TCDD suppressed pro-inflammatory (IFN-γ, TNF-α, and IL-6) and induced 
anti-inflammatory (IL-10, and TGF-β) cytokines. Moreover, TCDD also induced to Tregs 
that were antigen-specific (Vβ8+Foxp3+) and immunosuppressive.  
Interestingly, miR analysis in TCDD- treated T cells revealed significant 
alterations in the expression of miRs that were directed towards induction of Foxp3+ 
Tregs.  Our data suggested that TCDD-induced over-expression of miR-491 and miR-
148a may cause demethylation within Foxp3 promoter region by targeting DNMT3a and 
DNMT3b, and consequent acetylation of histone H3. Increase in acetylated histone H3 
may lead to the interaction of KLF10/SP-1 and potential induction of Foxp3.  
Interestingly, miR-31, which was down regulated following TCDD treatment, was found 
to be complementary to the 3’-UTR of Foxp3, CYP1A1 and SP-1. Importantly, miR-31 
directly targeted Foxp3 as shown using transfection experiments.  Moreover, miR-26b, 
which targets KLF10, was also down regulated in TCDD treated groups.  Together, our 
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studies identified TCDD-mediated alterations in the expression of several miRs that 
either directly or through epigenetic pathways, induce the expression of Foxp3 in 
antigen-activated T cells.   
In the current study, we used SEB, an enterotoxin produced by a ubiquitous 
Gram-positive coccus, Staphylococcus aureus (S. aureus), which has been classified as a 
super antigen 151 to study the effect of TCDD on Tregs.  SEB is listed as a category B 
priority agent by Center for Disease Control and Prevention due to its potential usage in a 
bioterrorist attack 152. SEB is the main cause of nosocomial infections, acute and fatal 
respiratory distress and toxic shock syndrome153,154,155.  SEB can activate ~ 20% of T 
cells by binding both to the non-polymorphic regions of the Major Histocompatibility 
Molecules (MHC) class-II on Antigen Presenting Cells (APC) , and to the variable region 
of the β chain of the T cell receptor (TCR)  such as Vβ8 TCR 156.  Thus, in addition to 
studying the effect of AhR activation on the enterotoxin, use of SEB provided us an 
opportunity to directly study antigen-specific Tregs that were Foxp3+ and Vβ8 TCR+. 
We also used Foxp3/GFP knock-in mice so that we could sort the Foxp3+ Tregs 
there by giving us a tool to study the epigenetic changes in purified Treg population.   
Numerous chemicals can activate AhR including environmental contaminants such as 
TCDD, and other compounds such as tryptophan derivatives, flavonoids and biphenyls 
[1-4]. AhR ligands can be divided into nonbiological/synthetic or biological compounds 
resulting from natural processes 157 . FICZ is a tryptophan photoproduct, with structural 
similarity to a high affinity natural AhR ligand, FICZ. While AhR was identified in the 
context of xenobiotic metabolism and toxicity, its role in immune system regulation is 
beginning to unravel 158.  The ability of TCDD to induces suppressor T cells was 
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demonstrated as early as 1984, using mouse chimeras 159. However, further studies were 
limited because no specific marker was identified on such suppressor T cells until the 
discovery of Foxp3, on CD4+ T cells, which were then designated as Tregs 160 .   
There have been conflicting reports on the nature of TCDD-induced Tregs.  One 
group suggested that the Tregs induced by TCDD are CD4+CD25+ but may not express 
Foxp3 161.  Studies from our own lab also showed that TCDD triggers Tregs that are 
Foxp3+  162.  The differences in these studies can be explained by the nature of disease 
models studied.  For example, in the study that found TCDD to not induce Tregs that 
were Foxp3+, the authors used graft-vs-host response  161 whereas in the study where 
TCDD was shown to induce Foxp3+ Tregs, EAE was used as a model 162.  In EAE, it is 
well established that the clinical disease primarily rests on the balance between Tregs and 
Th17 cells.  In the current study, we clearly demonstrated the induction of Foxp3 on SEB 
antigen-activated  Vβ8+ T cells following TCDD treatment.  
miRs have emerged as important regulators of gene expression. In the current 
study, we explored the differential expression of miRs in the presence of TCDD during 
super-antigen-induced activation of T cells. We first carried out an affymetrix analysis of 
miR expression followed by Molecular Activity Predictor (MAP) feature in Ingenuity 
Pathway Analysis (IPA) software to identify the down-stream effect of differential of 
miR expression.  Such an approach provided a global analysis of differentially regulated 
miRs in TCDD induced immunosuppression. Specifically, we also identified two 
miRs___miR-184a, and miR-491___ as the important regulators of TCDD-induced Tregs in 
super-antigen- activated T cells because of their ability to modulate DNMT expression 
and modification of chromatin configuration.  The connection between miR-148a and 
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DNMT1 expression has been studied in cancer models.  For example, a recent study 
reported the dramatic suppression of miR-148a in pancreatic cancer tissues and that there 
was an increase seen in DNMT1 expression 163.  Over-expression of miR-148a in ASPC-
1 cancer cells led to a decreased level of DNMT1 and suppression of metastasis. Also, 
over-expression of miR-148a was seen in CD4+ T cells in both patients with lupus and 
lupus-prone MRL/lpr mice characterized with demethylation of  promoter of 
autoimmune-associated methylation-sensitive genes, such as CD70 and LFA-1.  In the 
current study, we found that up-regulation of miR-148a upon TCDD administration 
contributed to hypo-methylation at Foxp3 regulatory region by potentially targeting 
DNMTs, which may lead to increased Foxp3 induction.  We also noted that over-
expression of miR-34a following TCDD treatment in SEB-activated T cell, led to 
suppression of HDAC1 and subsequently resulted in H3 acetylation at Foxp3 regulatory 
region. Another study elucidated the therapeutic manipulation of miR-34a in breast 
cancer cases, by demonstrating HDAC1 as the potent target for miR-34a, which led to 
deacetylation of HSP70/K246 and subsequently resulted in inhibiting autophagic cell 
death and cancer cell survival 164. In agreement with the previous findings, we uncovered 
the HDAC-1 inhibitory function of TCDD at Foxp3 promoter region via miR-34a 
differential regulation. 
Several epigenetic markers, such as histone methylation and acetylation, cytosine 
residue methylation in CpG dinucleotides of the promoter regions, have been identified 
as gene transcriptional regulators 165,166,167.  We investigated the methylation status of 
conserved CpG dinucleotides in the upstream of FoxP3 enhancer regions of TCDD-
exposed SEB-activated Tregs and found it to be hypomethylated when compared to 
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vehicle controls.  In a recent report, Kim et al identified the differential methylation state 
at Foxp3 regulatory region, and demonstrated that inhibiting the methylation with 5-
azacytidine or using a lentiviral vector and siRNA to knock down DNMT1 in 
CD4+CD25− cells, resulted in demethylation of Foxp3 promoter and subsequently led to 
elevated Foxp3 expression 168. Furthermore, when they examined the methylation status 
of Foxp3 promoter under Treg differentiation condition by addition of TGF-β, they found 
demethylation at both the mouse promoter and the cAMP response element binding 
protein (CREB) binding region 168  .In contrast, Janson et al. reported that human TGF-β 
induced-Tregs did not exhibit demethylation of human Foxp3 promoter region 169. 
Previous studies from our laboratory demonstrated that TCDD induces 
demethylation of Foxp3 promoter region which leads to Foxp3 upregulation and 
enhanced Treg differentiation 162.   In the current study, we uncovered additional 
mechanistic effect of TCDD on methylation profile of Foxp3 regulatory region of 
activated-Tcells and introduced TCDD as the potent DNMT inhibitor in SEB-activated T 
cells. Our data revealed that DNMT inhibitory function of TCDD leads to hypo-
methylation of Foxp3 regulatory region in SEB-activated T cells and increased Foxp3 
induction. Busbee et al. reported that HDAC inhibitors were able to suppress SEB-
induced inflammation and that HDAC1 was one the most significantly modified HDACs 
131.   Interestingly, we also found HDAC-1 to be highly suppressed upon TCDD treatment 
in SEB-activated T cells. 
In the current study, we found hypo-methylation and H3 acetylation of Foxp3 
regulatory region.  We believe that this opens the chromatin configuration and enables  
KLF10/Sp1 transcription factors to bind to their recognition sequences and subsequently 
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cause stable expression of Foxp3. The active role of the transcription factor Sp1 is 
protection of  CpG islands from  de novo methylation, which is well established in earlier 
studies 145,146,147.  Previous study demonstrated that deletion of Sp1binding site in mouse 
adenine phosphoribosyhransferase (aprt) gene resulted in hyper-methylation of CpG 
islands in transgenic mice 170. Thus, Sp1 involved in many cellular processes including 
cell differentiation, cell growth and development, immune function and inflammation, by 
triggering chromatin remodeling. KLF10, a member of the Krüppel-like family of 
transcription factors, binds to Sp-1-GC rich DNA sequences and regulates the 
transcription of a number of genes 148. Other studies revealed the critical role of KLF10 in 
regulation of Foxp3 expression in Tregs by interacting with transcription factor Sp1 171. 
Deletion of KLF10 in Tregs fosters atherosclerosis in ApoE(-/-) mice with increased  
peripheral inflammation.  
We also validated the miRs regulating the expression of these transcriptional 
factors. We demonstrated down-regulation of miR-26b and miR-31 following TCDD 
exposure in SEB-activated T cells which led to re-expression of KLF10/Sp1 and Foxp3 
induction.  Interestingly, for the first time we identified the specific dual role of miR-31 
in TCDD-mediated upregulation of CYP1A1 and Foxp3. Furthermore, we conducted 
transfection studies with synthetic miR mimic and particular customized target gene 
protector to validate the direct targeting of CYP1A1 and Foxp3 with miR-31. To our 
knowledge, this study is the first to report the functional role of miR-31 in regulation of 
inducible Tregs with TCDD. The comprehensive report of differential expression of 
miRs, which influences different canonical pathways, following TCDD administration in 
SEB-activated T cells, has been provided in supplementary data.  
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Collectively, this study has identified several complex epigenetic regulatory 
pathways of Foxp3 induction by TCDD, which also helps in the better understanding of 
mechanisms employed by epigenetic markers to promote differentiation of 
immunosuppressive Tregs.  
 
 
 
 
 
FIGURE 2.1 Treatment with TCDD in vivo reduces percentage and number of 
SEB-specific Vβ8 T cells. (A) Groups of 5 C57BL/6 mice were given injections of 10ug 
of SEB in each hind footpad only once. Mice were given ip injection of TCDD (10μg/kg) 
simultaneously with SEB injection. On the peak response day 3, PLN were analyzed. The 
ratio (A) and total cell number (B) of Vβ8+  CD3+T cells is depicted as mean+/- SEM.  
Cytokines were measured in the serum (C) of mice or in the supernatants (D) of the 
cultured-popliteal lymphocytes using ELISA.  Data represent mean+/- SEM.  
SEB+TCDD vs SEB+Vehicle, *p< 0.05 by Student’s t-test.   
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FIGURE 2.2 TCDD induces Tregs and anti-inflammatory cytokines against SEB 
C57BL/6 mice were treated with SEB and TCDD, as described in Figure 1 legend.(A) 
flow cytometric analysis CD4+Foxp3+ Tregs in PLN. (B) Cytokines  were measured in 
the supernatants of the cultured-popliteal lymphocytes using ELISA.  (C)Regulatory T 
cells were isolated by sorting from the Foxp3/GFP knock-in mice, treated with 100 nM 
TCDD and added to co-cultures of LN cells activated with SEB at two different ratios of 
Tregs: SEB-activated T cells (1:4, and 1:8). Cell proliferation was measured by 3H-
thymidine uptake assay (D) Cytokines were measured in the supernatants of the co-
cultures as described above.  (E) PLN cells stained for Vβ8 in Foxp3/GPF gated 
population. SEB+TCDD vs SEB+Vehicle, *p< 0.05 by Student’s t-test.   
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FIGURE 2.3.  miR expression profile in SEB-injected mice treated with TCDD  
miRs was isolated from CD4+ PLN  cells from mice exposed to Vehicle+SEB or 
TCDD+SEB  (A) Differential expression heat map of 609 miRNAs between SEB+TCDD 
or SEB+Vehicle groups. (B) Cluster analysis of microRNAs shows that 37 miRs were up 
regulated while 51 were down-regulated in SEB+TCDD mice compared to SEB+vehicle 
group. (C) Interaction between the microRNAs and their target genes was assessed by 
ingenuity pathway analysis (IPA) software. Fig Several pathways are affected with target 
genes and microRNA differentially regulated upon TCDD exposure. 
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FIGURE 2.4 In vivo miR expression and target gene expression for miR-148a and 
miR-491.Mice were exposed to SEB+TCDD or SEB+Vehicle as described in Fig 1 
legend. Total RNA was isolated from popliteal CD4+ T cells and expression levels were 
measured by qRT-PCR. (A) miR-148a (B) miR-491 (C) DNMT3b (D) DNMT3a (E) 
DNMT1. ChIP assay on Foxp3 enhancer elements using GFP+ cells from Foxp3/GFP 
knock in mice with (F) anti-DNMT1, (G) anti-DNMT3b, (H) anti-DNMT3a, and (I) anti-
MeCP2. Data shown are representative of 2-3 independent experiments for each panel 
(Mean+/- SEM, Student’s t-test *, p <0.05) 
             
FIGURE 2.5 miR-34a regulates Histone H3 acetylation in Tregs via HDAC1 
Mice were exposed to SEB+TCDD or SEB+Vehicle as described in Fig 1 legend. Total 
RNA was isolated from popliteal CD4+ T cells and expression levels were measured by 
qRT-PCR. (A) miR-34a (B) HDAC1. ChIP assay on upstream of Foxp3 enhancer using 
the isolated GFP+ cells from Foxp3/GFP knock in mice with (C) anti-AcH3 and (D) anti-
H3K9. Data shown are representative of 2-3 independent experiments for each panel.( 
Mean+/- SEM, Student t-test *, p <0.05) 
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FIGURE 2.6 Foxp3 promoter of TCDD-induced Tregs is transcriptionally active. 
Mice were exposed to SEB+TCDD or SEB+Vehicle as described in Fig 1 legend. Total 
RNA was isolated from popliteal CD4+ T cells and expression levels were assayed using 
qRT-PCR. (A) miR-31 (B) miR-26b (C) KLF10 (D) Sp1.  ChIP assay upstream of Foxp3 
enhancer using the GFP+ cells isolated from Foxp3/GFP knock in mice with (E) anti-
KLF10 (F) anti-Sp1.  Data shown are representative of 2-3 independent experiments for 
each panel. ( Mean+/- SEM, Student t-test *, p <0.05) 
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FIGURE 2.7 miR-31 inhibition leads to induction of Foxp3P3 and CYP1A1 
SEB-activated cells were transfected with customized inhibitor for miR-31 or were mock 
transfected. The expression levels of Foxp3 were quantified by (A) qRT- PCR.  SEB-
activated cells were transfected with miR-31 mimic and specific custom-designed Foxp3 
target protector. The expression levels of Foxp3 were quantified by (B) qRT- PCR and 
(C) Western blot analysis. Co-transfection of SEB-activated lymphocytes with mimic-
miR-31 and CYP1A1 target protector was conducted in vitro. The expression levels of 
CYP1A1 were quantified by (D) qRT- PCR analysis.  (Mean+/- SEM, Student t-test *p< 
0.05 , **p< 0.01 ).  miR-31/Foxp3 alignment with the mirSVR score: -0.6807 (down-
regulation score) miR31/CYP-1A1 alignment with mirSVR score:-0.1340 (down-
regulation score)has been depicted. 
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                                                                             Supplementary Figure 2.1 
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Supplementary figure 2.1 TCDD induces AhR signaling by altering miR profile in 
SEB-activated T cells.Mice were exposed to SEB+TCDD or SEB+Vehicle as described 
in Fig 1 legend. (A) Overlay of AhR signaling canonical pathway with miRs that were 
significantly changed upon TCDD administration in SEB-activated T cells. Predicted 
downstream effect of differentially expressed miRs using Molecular Activity Predictor ( 
MAP). qRT- PCR analysis was carried out for (B) miR-455 (C) miR-351(D) ARNT(E) 
CYP1A1. (Mean+/- SEM, Student t-test *p< 0.05 , **p< 0.01 ). 
 
 
 
Table2.1: candidate targets for filtered miRs, along with their seed sequence and 
respective fold change. The highly predicted and experimentally observed targets has 
been listed. 7 mer seed sequence are in bold red. 
 
miRNA		 MiRBase	#	 Chr.	 Sequences		 Experimentally	observed/highly	predicted	targets	 FC		
miR-148a	 NIMAT0000516	 Chr6	 UCAGUGCACUACAGAACUUUGU	
	
DNMT1,DNMT3B,DNMT3A	
	
1.737	
miR-491	 NIMAT0003486	 Chr4	 AGUGGGGAACCCUUCCAUGAGG	
	
DNMT3B,STAT3,STAT5B,GSK3B,Foxo1,Foxo3,TGFβR2	
	
1.674	
miR-34a	 NIMAT0000542	 Chr4	 UGGCAGUGUCUUAGCUGGUUGU	
	
	
HDAC1,SOCS4,SOCS7,SIRT1,P53	
	
2.267	
miR-31	 NIMAT0000538	 Chr4	 AGGCAAGAUGCUGGCAUAGCUG	
	
Foxp3,CYP1A1,Sp1,STAT5A,Kpna1,TGFβR2,GSK3B,STAT5B	
	
-
1.605	
miR-26b	 NIMAT0000534	 Chr1	 UUCAAGUAAUUCAGGAUAGGU	
	
KLF10,PTGS2,PTEN,CTGF,GSK3B,MAP3K1,RB1	
	
-1.83	
miR-351	 NIMAT0000609	 ChrX	 UCCCUGAGGAGCCCUUUGAGCCUG	
	
CYP-1A1,BAK-1,CASPASE6,CASPASE7,MAP2K7,CDK6	
	
-
1.876	
miR-455	 NIMAT0003485	 Chr4	 UAUGUGCCUUUGGACUACAUCG	
	
ARNT,ARNT2,CYP-20A1,CYP-4F3,MYD88	
	
-
1.571	
	
	
 
 
Supplementary figure 2.2. Schematic of the role microRNA and epigenetic 
regulators play in TCDD induced Foxp3 expression in Tregs  
Supplementary Figure 2.2 
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CHAPTER III:  BLOCKADE OF CB1 CANNABINOID RECEPTOR ALTERS 
GUT MICROBIOTA AND ATTENUATES INFLAMMATION AND DIET-
INDUCED OBESITY. 
 
                                                    3.1 INTRODUCTION 
Gut microbiome is the key feature in maintaining the whole body energy balance 
by affecting the glucose metabolism and low-grade chronic inflammation associated with 
obesity. Previous studies have shown that obese mice had broad phylum level changes in 
their microbial community and fecal transfer from obese mice into gnotobiotic lean mice 
conferred many inflammatory features of diet- induced obesity to the recipients 172,173. 
Correlation between progression of metabolic syndrome and alteration in gut microbial 
community has been reported in mice with deletion of Toll-Like Receptor 5(TLR5) gene 
174.  Fecal transfer from the TLR5 deficient mice to wild type germ-free mice mimic 
multiple symptoms of metabolic disease in the recipient mice. 
  Microbial community of the gut consists of symbionts (beneficial), neutral 
(commensals) as well as detrimental (pathobionts) microorganisms. The homeostasis of 
these essential allies can modulate the host health and function 175.  The mutual 
interaction of gut microbiota and host immune system is necessary in maintaining their 
symbiotic relationship176,177,178,179,180.  Gut immune system determines colonization of 
microbial community in gut and contributes to the interaction of host-microbiome 181.  
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Metabolic endotoxemia and inflammation in obese mice may result from the 
chronically higher levels of lipopolysaccharide (LPS) and pro-inflammatory cytokines182. 
Higher intake of saturated fat leads to the disruption of multi-layered mucus structures 
and tight junctions in gut, leading to permeability of gut barrier and consequent leakage 
of LPS in circulation 183. LPS absorption by gut enterocyte chylomicrons results in robust 
release of systematic LPS, which is believed to contribute to inflammatory and metabolic 
disorders 184. Macrophages are the first-line of target of LPS and their retention in 
adipose tissue is implicated in pathophysiology of diet-induced obesity and metabolic 
syndrome 185,186.  
 Numerous studies have demonstrated that diet-induced obesity and associated-
inflammatory disorders may result from dysregulation of endocannabinoid (eCB) system. 
Augmentation in eCB levels in plasma and adipose tissue as well as modulation of CB1 
receptors has been reported in obese individuals 187,188,189,190,191. Alterations in gut eCB 
system is implicated in the dysregulation of LPS level, gut integrity disruption, chronic 
inflammatory state of gut, and dysbiosis of gut micro-flora 192. Previous study has shown 
that LPS leads to dysregulation of eCB system in macrophages 193. LPS causes robust 
production of endogenous ligands of cannabinoid receptors, specifically Anandamide 
(arachidonylethanolamide, AEA) in adipose tissue macrophages, which contributes to 
exacerbation of chronic inflammation in visceral fat, hyperglycemia and insulin 
resistance  194 . 
Numerous pharmacological, preclinical and clinical studies indicate that blockade 
of cannabinoid CB1 receptor can significantly improve obesity complications and 
multiple risk factors of metabolic syndrome 195,196,197,198,199,200,201.   However, the direct 
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implications and precise physiological role of CB1 receptor antagonist in the modulation 
of gut microbial communities in diet-induced obesity has not yet been fully determined. 
Herein, for the first time, we uncovered the changes in gut microbial community in a 
mouse model of diet-induced obesity treated with CB1 antagonist, SR41716A.  In order 
to demonstrate the effect of SR141716A on gut microbiota beyond its effect on diet 
intake and weight loss, we included pair-feeding controls as well as body weight-matched 
controls. The current study provides compelling evidence that targeting the eCB system 
in diet induced obesity model by utilizing SR141716A as the CB1 receptor blocker, 
remodels the gut microbial colonization and subsequently leads to amelioration of pro-
inflammatory macrophages and metabolic parameters.  
  
                             3.2 MATERIALS AND METHODS 
 
Animals and SR141716A treatment- 
 
Diet-induced obesity was studied in male C57BL/6J mice (Jackson Laboratory, 
Bar Harbor, ME) by feeding high fat diet of 60 kcal% fat (Research Diets Incs, New 
Brunswick, NJ). Lean age-matched controls were fed with low fat diet of 10 kcal% fat, 
and match 17% sucrose in HFD (Research Diets Incs, New Brunswick, NJ). Intervention 
treatment with SR141716A was performed after 12 weeks of high fat diet. Pair-fed and 
body weight-matched controls were included in the study in order to investigate the effect 
of SR141716A treatment beyond its effect on diet intake and body weight loss. Pair-fed 
and body weight matched controls were included as previously described 198. SR141716A 
was administered to the DIO mice in 0.1% tween 80 for four weeks, (10mg/kg/daily). 
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Controls lean (LFD), DIO (HFD), pair-fed to SR141716A(PFSR) and body weight-
matched (BWM) controls were treated with vehicle. Body composition was assessed by 
using a Dual-Energy X-ray Absorptiometry (DEXA, LUNAR, Madison, WI) at the 
baseline of the study; mice were normalized to the different groups based on the fat mass. 
Food intake was monitored daily and changes in body weight was recorded daily after 
starting the intervention treatment. Mice were sacrificed under anesthesia and different 
tissues were dissected. Metabolic parameters were collected at both baseline and prior to 
the sacrifice day. All mice were housed at the (American Association for the 
Accreditation of Laboratory Animal Care-accredited (AAALAC) animal facility at the 
University of South Carolina, School of Medicine (Columbia, SC).  All procedures were 
performed according to NIH guidelines under protocols approved by the Institutional 
Animal Care and Use Committee. 
 
Assessment inflammatory profile- locally and systematically- 
Cytokines levels were measured in plasma and quantified using Bio-Plex 
multiplex immunoassay system (Bio-Rad, Hercules, CA), as described by us 
previously 202. RNA was isolated from epididymial fat pad using the E.Z.N.A.® Total 
RNA Kit (Omega Bio-tek, Norcross, GA). The purity and concentration of the RNA was 
confirmed spectrophotometrically with Nanodrop (Thermo Scientific,	Waltham, MA). 
Total RNA was converted to cDNA using the miScript cDNA synthesis kit (Qiagen, 
Valencia, CA) according to the manufacturer's instructions.  SsoAdvanced™ Universal 
SYBR® Green Supermix kit (Bio-Rad,Hercules, CA) was used to analyze gene 
expression , and GAPDH was used as the housekeeping gene. List of all the primers have 
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been provided in supplementary Table 4. Complete Blood Cell count (CBC) was 
performed using hematological analyzer VetScan HM5 (ABAXIS, Union City, CA). 
Circulating LPS level was quantified as previously described  203. Colonic 
myeloperoxidase was assessed according to the manufacturer’s instruction (Abcam, 
Cambridge, MA) 204. 
Free fatty acid was quantified in serum according to the manufacturer’s instruction (Zen-
Bio Inc, Research Triangle Park, NC) 
 
Isolation of adipocytes and infiltrated cells in adipose tissue- 
Fat pads of mice were excised and placed in gentleMACS C Tubes (MACS 
Miltenyi Biotec, San Diego, CA) containing digestion medium (HBSS, 2mg/ml 
collagenase (Sigma-Aldrich, St. Louis, MO) and 2% BSA, and homogenized by utilizing 
gentleMACS Dissociator (MACS Miltenyi Biotec, San Diego, CA). After incubation at 
37 °C for 30 min with shaking, the cell suspension was filtered through a 100-µm filter 
and then spun at 1200 rpm for 10 min to separate floating adipocytes from the Stromal 
Vascular Fraction (SVF) pellet. Supernatant was aspirated completely and cells were re-
suspended in FACS buffer for flow cytometry. Samples were digested until the majority 
of the SVF population were separated from the adipose tissue.  
 
Glucose and Insulin tolerance test- 
Glucose tolerance test was carried out as previously described  205. After 
determining fasting blood glucose, each animal received a glucose gavage 1.5g/KG body 
mass of glucose (25% D-glucose, Sigma, St.Louis, MO) .  Blood glucose levels were 
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determined after 15, 30, 60 and 120 minutes. Insulin-tolerance tests were performed on 
un-fasted animals by injecting i.p 1.5 U/Kg body mass of insulin (HumilinR 100U/ml).  
Blood glucose levels were assessed after 15, 30, 60 and 120 minutes. Total cholesterol 
(TC), HDL-C, LDL-C, and triglycerides at the baseline and after intervention were 
quantified as previously described 206,207 .Homeostatic model assessment (HOMA) index 
was calculated as follow: insulin resistance index = fasting insulin (µU/ml) x fasting 
glucose (mmol/l)/22.5 208   . 
 
Measurement of adiposity and macrophage retention in adipose tissue- 
The mean adipocyte size in epididymal adipose tissue was quantified with imageJ 
analysis software (National Institution of Health,NIH) as previously described 206. 
Macrophage retention in adipose tissue was quantified per 100 adipocytes by Spot Studio 
v1.0 Analysis Software (Advanced Cell Diagnostics, Hayward, CA). 
 
Mucosal layer staining and thickness- 
Mouse colon fixation and mounting was performed as previously described 209. 
Periodic acid Schiff was conducted according to the manufacturer instruction (Abcam, 
Cambridge, MA) . The thickness of mucosal layer was assessed by analysis software 
package Gene 5(Cytation5, BioTek, Winooski, VT) and MetaMorph (Molecular Devices, 
Wokingham, UK). 
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Gut permeability in vivo- 
Mice were deprived of food and water for 4 hours. Intestinal permeability was 
measured after they received dextran-4kDa-FITC (Sigma, St. Louis, Missouri) by oral-
gavage (500 mg/kg body weight, 125 mg/ml). Measurements were taken as described 
earlier 183. Serial dilution of FITC–dextran in the serum were performed to generate the 
standard curve.  
 
Measurement of AEA and 2-AG in serum and tissue- 
Tissue lipids were extracted as described earlier 193.  Extracted lipid from serum 
and adipose tissue was processed as previously described 210.  The levels of 
endocannabinoid from tissue and serum was quantified by triple quadrupole mass 
spectrometer with electrospray ionization at the Mass Spectrometry Center at the 
Department of Chemistry and Biochemistry, University of South Carolina.  Samples were 
introduced into Micromass Quattro-LC through a liquid chromatograph.  It used in 
tandem Mass spectrometry (MS/MS) mode for qualitative and quantitative analyses. 
 
Microbial analysis after SR141716A intervention treatment of obese mice- 
16S rRNA gene sequencing was performed on 25 fecal samples from Diet-
Induced obese (HFD), SR141716A treated-DIO (HFD+SR) mice, Pair-fed to 
SR141716A (PFSR) mice, body-weight matched to SR141716A (BWM) and age 
matched low fat diet (LFD) controls (n=5 mice per group). DNA was extracted from 
frozen extruded feces using the QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) 
according to the manufacturer's instructions. Purified DNA was indexed with TrueSeq 
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DNA PCR-free LT Library preparation kit for low-throughput studies (Illumina, San 
Diego, CA) according to the manufacturer's instructions. DNA was PCR-amplified using 
primers for paired-end 16s community sequencing on the Illumina MiSeq platform using 
bacteria/archaeal primer sense 319F/ anti-sense 806R targeting hyper-variable regions 
V3-V4 of the 16S rRNA gene. Each primer is followed by a barcode identifier generated 
specifically for the set of primers. Phix V3 (25%) was used as a control for Illumina 
sequencing runs. The library was sequenced on 300 paired-end MiSeq run as previously 
described at John’s Hopkins Deep Sequencing and Microarray Core facility 211. 
 
16S rRNA gene sequence analysis- 
The sequences were preprocessed and demultiplexed with CASAVA 1.8.2 during 
conversion of bcl to Fastq 212. The demultiplexed sequences were quality filtered for 
chimeras, using the Quantitative Insights In to Microbial Ecology (QIIME, version1.9.0) 
software package to avoid false diversity. Forward and reverse Illumina reads were 
joined using the SepPrep method (https://github.com/jstjohn/SeqPrep). We used QIIME 
default parameters for quality filtering as described previously 209. Sequences were 
assigned to Operational Taxonomical Units (OTUs) using the closed reference OTU 
picking protocol against the Greengenes database	with a 97% threshold of pairwise 
identity. 	
Beta-diversity of the gut microbiome was evaluated by weighted UniFrac-based 
principle co-ordinates algorithm. The analysis was performed using the abundance matrix 
of genus-level OTUs in different samples, rarefaction was performed (10,000 sequences 
per sample) and used to compare abundances of OTUs across samples.  Exceptions from 
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study groups were observed, confounded by variations in other environmental exposure 
and genetics factors on these microbiomes. Chao1 index was calculated to estimate the 
species richness of present organisms in the community.  
Specific quantitative PCR (qPCR) targeting the employed fecal samples in 16S 
rRNA gene sequencing was performed using Quantifast SYBER Green PCR Kit (Bio-
Rad, Hercules, CA). Abundance of Akkermansia muciniphila (A. muciniphila), 
Lanchnospiraceae and Erysipelotrichaceae were quantified by specific primers 
(Supplementary Table 4). Total microbial DNA was quantified and addressed as the 
endogenous control, we used universal bacterial primers 319F and 806R— the same used 
for 16S sequencing.  
 
Short-chain fatty acids quantification by Gas chromatography with flame Ionization 
Detector (GC-FID)- 
Cecal content (100 mg) were homogenized in in 400 µl of deionized water, 
followed by acidification with 25% metaphosphoric acid (Sigma-Aldrich, St. Louis, MO) 
at a 1:5 ratios (1 volume of acid for 5 volumes of sample) for 30 min on ice as previously 
described 213. Fatty acid was then isolated from the samples followed by centrifugation at 
12,000g for 15 minutes at 4 °C. Supernatants were filtered over Ultrafree MC column 
with .22 µm pore size (EMD Millipore, Billerica, MA), and elute was stored at -80 until 
it was analyzed by GC-FID.   
SCFA concentrations in specimens were quantified according to a modified 
method as described earlier 214 . Calibration standards were prepared as aqueous stock 
solutions using the following fatty acids at the given concentration; acetic, propionic, and 
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n-butyric at 400 mM,  isovaleric and valeric 200 mM, isobutyric 100 mM,  caproic and n-
heptanoic 50 mM. Each standard was injected to identify their retention times. Standard 
mixture was prepared at several concentrations suitable for the samples. Internal standard 
(IS) 2-ethylbutyric acid was added at 0.30 mM to the standard mixtures as well as to each 
sample before injection. Standard mixture with the IS was used to determine the response 
factors. Samples were prepared by first thawing at room temperature, taking 100 µL of 
the samples in to a vial and adding 40 µL of acetone and 60 µL of 0.10 mM IS solution. 
Then the mixture was vortexed and centrifuged. The clear solution was transferred to a 
glass GC vial and used for analysis.  A HP 5890 gas chromatograph configured with 
flame-ionization detectors (GC-FID) for analysis of volatile organic compounds was used 
for this assay. Stabilwax®-DA Column (fused silica) of 30 m × 0.32 mm i.d. coated with 
0.50 µm film thickness was used. Helium was supplied as the carrier gas at a flow rate of 
15 mL/min. The temperature was programmed to achieve the following run parameters: 
initial temperature 100 oC, hold for 0.5 min, ramp 20 oC/min, final temperature 250 oC 
maintain for 5 min. The injected sample volume for GC analysis was 1 µL splitless and 
the total run time was 18.0 min.  
Response factors (RF) were calculated via dividing the peak areas of the 
responses by the respective concentrations of the standards. To quantify the peak area in 
terms of concentration, the relative response factor (RRF) was used. The RRF was 
calculated using the formula RRF = RFStandard/RFIS. The concentration of the samples was 
calculated using the following equation, Conc. samples = Peak AreaSample x (Conc. IS/ Peak 
AreaIS)(1/RRF) 
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Statistical Analysis- 
Data were presented as mean ± SD. Differences between two groups were 
assessed using the unpaired two-tailed Student’s t-test. ANOVA followed by Newman-
Keuls post hoc tests was performed to analyze differences between data sets that involved 
more than two groups. Generalized Estimating Equation (GEE) and Generalized Linear 
Mixed Model (GLMM) was performed to fit a repeated measurement logistic regression. 
Trapezoidal Rule in R was used to assess Area Under the Curve (AUC) from the 
replicated experiments.  Pearson correlation was performed in R with the cor () function 
in ggplot2.  In the figures, data with different superscript letters were used to indicate 
statistical significant differences in groups (p < 0.05). Data were analyzed using 
GraphPad Prism version 7.00 for Windows (San Diego, CA), Excel, R a language and 
environment for statistic computing (R Development Core Team, 2010), and IBM SPSS 
Statistics for Windows, Version 22.0. (Armonk, NY). 
                                               
                                            3.3 RESULTS 
 
Effect of SR141716A on diet intake, body weight and body composition 
Consistent with previous research studies, treatment of DIO mice with 
SR141716A (HFD+SR) transiently reduced calorie intake and induced weight loss as 
compared with vehicle-treated DIO mice (HFD) (Fig 3.1B,3.1C) 215,216. To assess the 
effect of SR141716A beyond its effect on weight loss and calorie intake, pair-feeding 
was conducted in diet-intake matched controls (PFSR), and diet intake was adjusted in 
body-weight- matched (BWM) controls (Fig 3.1 A). The transient reduction of calorie 
intake in HFD+SR mice during the first week, was diminished by day 9 of treatment, and 
 
 
59 
reaching even to the same intake as HFD group (Fig 3.1B).  However, we noted 
continuous weight loss in HFD+SR group through the end of treatment (Fig 3.1C). In 
order to maintain the same body weight in BWM group as HFD+SR group, the diet 
intake was restricted to even lower intake than HFD+SR group (Fig 3.1B).  
In order to examine the effect of SR141716A beyond its effect on calorie intake, 
the pair-fed DIO control (PFSR) mice were fed with the same amount of high fat diet as 
consumed by the SR141716A-treated DIO mice(HFD+SR). The weight loss pattern in 
PFSR group was similar with HFD+SR during the first two weeks of treatment, but then 
PFSR group started to gain weight and reaching a close body weight to HFD group by 
end of the treatment (Fig 3.1C). 
Correlation between changes in body weight and caloric intake within different 
groups, demonstrated consistent weight loss in HFD+SR group regardless of its high 
level of calorie intake close to HFD group (Fig 3.1D).  
Assessing body composition after 4 weeks of SR141716A intervention in DIO 
mice (HFD+SR) showed significant reduction in fat gain as compared with vehicle-
treated DIO mice (HFD), while there was no difference in lean mass (Fig 3.1E). 
Inasmuch as SR141716A-treated DIO mice (HFD+SR) demonstrated less fat mass when 
compared to body weight-matched control (BWM) , the data suggested that other factors 
are associated with use of SR141716A besides its effect on calorie intake and weight loss 
(Fig 3.1E). Lower fat mass within SR141716A-treated group (HFD+SR) has been 
characterized with less adiposity. Assessing the area of the adipocytes demonstrated 
significant shrinkage in adipocytes of the SR141716A-treated DIO mice (HFD+SR) 
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when compared to vehicle-treated DIO mice(HFD), pair-fed control(PFSR) as well as 
body weight-matched control (BWM) (Fig 3.1F).  
 Adipose tissue fibrosis, in obese phenotype is associated with an increase in local 
inflammation. The Picrosirius red fibrillar collagens were interspersed among the 
adipocytes in HFD group. SR141716A treatment in DIO mice (HFD+SR) resulted in a 
significant suppression of adipose tissue fibrosis and consequently further reduction in 
local adipose tissue inflammation and dysfunction (Supplementary Fig 3.1A, 3.1B).   
Lighter fat pad (mainly in epididymal fat pad) in SR141716A-treated DIO mice 
(HFD+SR) was associated with smaller liver when compared with vehicle-treated DIO 
(HFD), Pair-fed DIO control(PFSR), and body weight-matched control(BWM) (Fig 
3.1G) 
 
Effect of SR141716A on systematic and local inflammation 
Based on the active role of macrophages in initiation of inflammation in adipose 
tissue, we examined the changes in macrophage population in adipose tissue. Intervention 
treatment of DIO mice with SR141716A (HFD+SR) demonstrated significant reduction 
in the ratio of macrophages/adipocytes as compared with vehicle-treated DIO (HFD), 
pair-fed control(PFSR) and body weight matched-control(BWM) (Fig 3.2A). Flow 
cytometric analysis for the subset of macrophages showed significant reduction in both 
frequency and absolute number of pro-inflammatory M1 macrophages with SR141716A 
treatment (HFD+SR) when compared to vehicle-treated DIO controls (HFD) (Fig 3.2B, 
3.2 C). Inflammatory profile has been assessed by examining chemokines and cytokines 
in the serum for the systemic inflammation. Treatment of DIO mice with SR141716A 
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(HFD+SR) led to lower level of IL-17, MCP-1, Eotaxin and MIP-1α when compared to 
vehicle-treated  DIO mice (HFD) (Fig 3.2 D-3.2G). The same trend was seen with TNF-
α, IL-6 ,RANTES, MIP-1β and MIP-2 but the differences were not significant . Changes 
in LPS as the major simulator of macrophages has been assessed 217. The data showed 
there was significant reduction in LPS level in the serum of SR141716A-treated DIO 
mice (HFD+SR) as compared with vehicle-treated DIO (HFD), pair-fed DIO 
control(PFSR) and body weight matched-control (BWM) (Fig 3.2 H).  
We also investigated the inflammation profile of adipose tissue and colon locally 
and to that end, the mRNA level of RORγ, TNF-α, iNOS, and IL-6 were quantified in 
adipose tissue (Fig 3.2I-3.2L). Overall, intervention treatment of DIO mice with 
SR141716A (HFD+SR) led to improvement of inflammatory state of adipose tissue 
beyond its effect on diet restriction.  
Local inflammation in colonic tissue was also determined by assessing the level 
of myeloperoxidase. SR141716A-treated DIO mice (HFD+SR) showed significant 
improvement in colonic inflammation, independent of its effect on weight loss and diet 
intake (Fig 3.2M). 
We also observed a significant increase in both the percentage and numbers of 
CD4+GATA3+ Th2 cells (anti-inflammatory T cell subset) following treatment with 
SR141716A of DIO mice (HFD+SR) (Supplementary Fig 3.2 A,3.2B).  
Myeloid Derived-Suppressor Cells (MDSC) that are GR-1+CD11b+ have been 
identified as potent anti-inflammatory cells.  In the current study, we noted that MDSCs 
were induced with SR141716A treatment in DIO mice (HFD+SR) when compared to 
vehicle-treated DIO (HFD) (Supplementary Fig 3.2C, 3.2D). We also assessed the 
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changes in blood MDSCs. The data showed a significant decrease in MDSC with 
SR141716A treatment in the blood (Supplementary Fig 3.2E) thereby suggesting that 
they may be migrating to the site of inflammation (adipose tissue).  
Differential analysis of Complete Blood Cell (CBC) revealed significant 
leukocytosis in DIO mice (HFD) when compared to SR141716A-treated DIO (HFD+SR) 
and lean (LFD) mice. Leukocytosis in DIO mice was more pronounced in neutrophils 
subpopulation, which are the first responder to inflammation. Our data suggested that 
treating DIO mice with SR141716A reduces neutrophilic leukocytosis.  Furthermore, 
SR141716A treatment balanced the increased level of hemoglobin and HCT% in DIO 
mice. (Supplementary Table 3.1).  Taken together, our data suggested that intervention 
treatment of DIO mice with SR141716A (HFD+SR) attenuates systematic inflammation 
and metabolic endotoxemia.  
 
Effect of SR141716A on metabolic parameters  
Glucose Tolerance Test (GTT) and Insulin Tolerance Test (ITT) showed 
remarkable improvement in metabolic parameters in DIO mice when treated with 
SR141716A (HFD+SR) as compared with vehicle-treated DIO (HFD) and pair-fed 
(PFSR) controls (Fig 3.3A, 3.3B). Improvement in other serum metabolic parameters 
such as Fasting Blood Glucose (FBG), TGs, HDL, LDL, HOMA index as well as free 
fatty acid was also observed following SR141716A treatment in DIO (HFD+SR) when 
compared to vehicle-treated DIO (HFD) and pair-fed to SR141716A (PFSR) 
(supplementary Table 3.2, Fig 3.3) 
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Effect of SR141716A on gut barrier integrity  
SR141716A counteracted diet-induced colon mucosal barrier dysfunction during 
high fat diet feeding by modulating the mucosal thickness (Fig 3.4A, 3.4B). Mucus-
related genes expression, Mucin2 (Muc2) and Kruppel-Like Factor 4 (KLF4) were 
improved with SR141716A treatment in DIO mice (HFD+SR) as compared with vehicle-
treated DIO mice (HFD), pair-fed to SR141716A (PFSR) control and body weight-
matched (BWM) controls (Fig 3.4C, 3.4D). SR141716A didn’t show any effect on the 
Trefoil Factor 3 (Tff3) gene expression (Figure 3.4 E).  
In addition, we performed in vivo intestinal permeability assay using an FITC-
labelled dextran method. Less leakage in the gut of SR141716A-treated DIO mice 
(HFD+SR) was observed when compared to vehicle-treated DIO (HFD) and pair-fed to 
SR14716A (PFSR) controls (Figure 3.4 F) Taken together these data indicated that 
SR141716A intervention treatment in DIO mice (HFD+SR) ameliorates the 
compromised mucosal layer and gut leakage in DIO phenotype.  
 
Effect of SR141716A on Endocannabinoid system 
Obesity has been characterized with over activation of eCB system187. In the 
current study, we found that CB1 receptor expression was down-regulated with 
SR141716A treatment of DIO mice (HFD+SR) when compared to vehicle-treated DIO 
mice (HFD)  (Fig 3.5A) . Level of endogenous ligand of cannabionoid receptors in 
adipocytes and serum was assessed by LC/MS/MS.  We observed significant reduction in 
adipose tissue anandamide (AEA) in DIO mice treated with SR141716A (HFD+SR) 
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when compared to the control DIO mice (HFD) (Fig 3.5B, 3.5C). We were unable to 
detect significant levels of 2-AG in all samples.  
 
Effect of SR141716A on adipogenic related-genes 
Next, we investigated the effect of SR141716A on adipose tissue metabolism, 
which was assessed by RT-PCR for lipogenesis, oxidation and differentiation genes.  We 
observed that SR141716A treatment of DIO mice (HFD+SR) increased the mRNA 
expression of markers of lipid oxidation (carnitine palmitoyltransferase-1 (CPT1), acyl-
CoA oxidase (Acox1), peroxisome proliferator-activated receptor gamma coactivator-1 
alpha (PGC-1α), and peroxisome proliferator-activated receptor alpha (PPARα) (Fig 
3.6A),  and adipocyte differentiation (CCAAT/enhancer–binding protein-α (C/EBPα) and 
peroxisome proliferator-activated receptor γ (PPARγ)(Fig 3.6B). Changes in lipogenic 
properties of adipose tissue was examined with (acetyl-CoA carboxylase (Acc1) and fatty 
acid synthase (FASN) quantification (Fig 3.6C).  Together, our data suggested that the 
shrinkage in fat mass in SR141716-treated DIO mice (HFD+SR) was associated with an 
increase in lipid oxidation differentiation and lipogenesis.  
 
Effect of SR141716A on dysbiosis of gut microbiota in diet-induced obesity  
To test that role of gut microbiota, we performed 16S rRNA metagenomics 
sequencing against both variable regions (V3+V4) of fecal samples in different groups of 
our study (n = 5 per group), and rarefied to a depth of 10,000 reads per sample. We 
grouped microorganisms in Operational Taxonomic Units (OTUs) in order to standardize 
grouping based on 97% similarities in DNA sequence (Supplementary Table 3.3). The 
obtained data demonstrated that overall, microbial communities were strongly structured 
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by diet.   We observed significant separation between lean mice and DIO mice. 
Interestingly, principal coordinate analysis performed based on distance matrix 
demonstrated that microbial community structure was more sensitive to SR141716A 
treatment than dietary fat intake (Fig 3.7A).  In order to estimate the diversity of micro-
organisms in regard to their numbers and their similarities in abundance, Alpha diversity 
was calculated based on Chao1 index (Fig 3.7B). Relative taxa abundance area plots at 
the genus taxonomical level for individuals from the five populations was assessed by 
taking the OTU table at genus level as an input . Individuals were represented along the 
horizontal axis, and relative taxa frequency at the genus level was denoted by the vertical 
axis (Fig 3.7 C). Taken together, our data suggested that OTUs were differentially 
enriched within the different groups in our study. In order to investigate the exclusive 
effect of SR141716A in the gut-flora of DIO mice (HFD+SR), we conducted pair-fed to 
SR141716A (PFSR) and body-weight matched control to HFD+SR. Our data indicated 
significant enrichment of Akkermansia OTUs in DIO-treated mice with SR141716A 
(HFD+SR) as compared with both pair-fed obese (PFSR) and body-weight matched 
(BWM) controls. Interestingly, the significant reduction in immunogenic 
Lanchnospiraceae and Erysipelotrichaceae seen with SR141716A treatment was beyond 
the effect of SR141716A on the weight loss and diet intake restriction. Because the 
disruption in gut mucosal layer was improved in DIO mice with SR141716A treatment 
(HFD+SR), we investigated the effect of treatment on residential bacteria of mucosal 
layer, specifically Akkermansia muciniphila 218,219,220,221,222,223. 
Numerous studies have shown the inverse correlation between the abundance of 
A.muciniphila and metabolic syndrome. RT-PCR from the isolated fecal DNA 
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demonstrated significant enrichment in A.muciniphila colonization in SR141716A-
treated DIO mice (HFD+SR) as compared with vehicle-treated DIO (HFD), pair-fed to 
SR141716A (PFSR), and body weight matched to SR141716A (BWM) (Fig 3.7D). 
Previous studies have demonstrated that Lanchnospiraceae and Erysipelotrichaceae, 
within firmicutes phylum are implicated in gaining weight and induction of metabolic 
syndrome 224,225,226,227,228.   Our studies demonstrated that Lanchnospiraceae and 
Erysipelotrichaceae were significantly decreased in SR141716A-treated DIO mice 
(HFD+SR) as compared with vehicle-treated DIO (HFD) control. In addition, the RT-
PCR from the fecal content validated the 16s rRNA sequenced data (Fig 3.7E, 3.7F).  
 
Effect of SR141716A on Short Chain Fatty Acid (SCFA) in Diet-Induced Obesity 
In order to investigate the effect of SR141716 intervention treatment in DIO mice 
(HFD+SR), on Short Chain Fatty Acid (SCFA), we quantified the level of SCFA in 
serum, cecal and fecal content of mice. Interestingly, we found a significant increase in 
concentration of propionic acid, I-butyric as well as n-butyric acid, in cecal and fecal 
content of SR141716A treated DIO (HFD+SR) mice when compared with vehicle-treated 
DIO (HFD) mice (Fig 3.8A, 3.8B). The same trend was observed in concentration of 
acetic acid as well as valeric acid, but the changes weren’t significant. In order to 
evaluate the alteration in SCFA systemically, we assessed the concentration of SCFA in 
serum. Because the SCAFs are mostly abundant in colon and stool, the same trend but at 
the lower concentration than SCFAs in fecal and cecal content was observed in SCFAs of 
serum. (Supplementary figure 3.4) .  
                                                         
 
 
67 
3.4 DISCUSSION 
 
There is growing evidence to suggest that blockade of cannabinoid CB1 receptor 
possesses anorectic anti-obesity properties and modulates metabolic parameters in diet-
induced obesity 216,229,230,231 .  However, most of the previous studies did not fully 
investigate the effect of cannabinoid CB1 antagonist on chronic inflammation in DIO 
model.  Our study investigated both systematic and local inflammatory profiles in DIO 
model and demonstrated that intervention treatment of DIO mice with SR141716A, can 
ameliorate the obese phenotype and associated metabolic complications. Because there is 
a clear association between adipose tissue macrophage accumulation and metabolic 
dysfunction in DIO model, we investigated the effect of  CB1 antagonism on 
macrophages and it was remarkable to note that SR141716A treatment could suppress 
pro-inflammatory macrophages (M1) in adipose tissue and their associated cytokines 
(MIP-1α, MCP-1, and  plasma LPS). Indeed, blockade of cannabinoid CB1 receptors in 
mice fed a high fat diet reduced macrophage retention in adipose tissue, suppression of 
local and systematic inflammation as well as insulin resistance.  In the current study, we 
also observed improvement in colonic inflammation (MPO) in DIO model following 
SR141716A treatment. 
It is of the interest that blockade of cannabinoid CB1 receptor with SR141716A in 
obese mice resulted in attenuation of neutrophilic leukocytosis associated with obesity. 
One of the possible mechanistic effect of SR141716A on the neutrophilic leukocytosis 
can be attributed to the inhibition of the neutrophil elastase activity. Recent study 
identified that the neutrophilic leukocytosis in DIO mice exacerbate the chronic 
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inflammation in adipose tissue 232. Increase in neutrophil population is associated with 
more release of, a serine proteinase, elastase, which results in activation of Toll-Like 
Receptor 4 (TLR4) pathway, and massive release of chemo-attractants from the immune 
cells and adipocytes. Consistent with our findings, the neutrophilic knockout mice were 
protected from insulin resistance associated with obesity phenotype  232. The direct effect 
of blockade of cannabinoid CB1 receptor on neutrophils and their elastase activity 
warrant further investigation. 
In order to evaluate the effect of SR141716A treatment beyond its effect on 
calorie intake and weight loss, we conducted pair-fed to SR141716A (PFSR) and body 
weight-matched (BWM) to SR141716A-treated obese (HFD+SR) mice as controls 198. 
Pair-fed to SR141716A (PFSR) consumed the same amount of high fat diet as the 
SR141716A-treated obese mice (HFD+SR). Diet intake was adjusted in body weight-
matched (BWM) controls to perpetuate the same weight loss pattern as in SR141716A-
treated obese mice (HFD+SR). Our study demonstrated that transient reduction in 
calories intake and sustained weight loss in SR141716A-treated obese mice (HFD+SR), 
was associated with less adiposity and smaller fat mass. The smaller adipocytes in 
SR141716A-treated obese mice (HFD+SR) was associated with the significant reduction 
in fat storage. Previous studies have shown that SR141716A may trigger futile calcium 
cycling, which results in enhanced whole body energy expenditure 216,233.  Therefore, one 
potential explanation for SR141716A-induced reduction in fat mass independent of 
calorie intake, is enhanced lipolysis and lipid oxidation to maintain ATP for futile cycle 
(calcium and substrate).  
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In contrast to the previous studies, our data demonstrate that blockade of 
cannabinoid CB1 receptor with SR141716A in obese mice contribute to increased 
lipogenesis 198,234,235. Interestingly, a previous study uncovered the regulatory role of LPS 
in mediating inhibitory effect on lipogenesis, on cultured adipose tissue via PPAR-γ 
blockade 192. In conjunction with our data, several studies have shown that over-activity 
of endocannabinoid system in DIO model, is associated with increased LPS levels and 
inflammation 192 .Furthermore, we found that SR141716A-treated obese (HFD+SR) mice 
demonstrated improvement in gut permeability as compared to vehicle-treated obese 
(HFD) mice. Consistent with our study, earlier reports demonstrated improvement in gut 
permeability in SR141716A-treated ob/ob obese mice by induction of two tight junction 
proteins, occludin and ZO-1 183,224.  Thus, increase in lipogenesis with SR141716A 
treatment may result from less gut permeability which prevents the LPS-inhibitory effect 
on lipogenesis. These data also suggest that cross-talk between endocannabinoid system 
and LPS may modulate adiposity. 
It is exciting to note that the protective effect of SR141716A against obesity and 
metabolic disruption observed in our study, could be explained by the potential link 
between gut microbial community and endocannabinoid system. Enhanced 
endocannabinoid (eCB) system activity including higher level of endocannabinoids in 
plasma and adipose tissue as well as changes in cannabinoid CB1 receptor expression has 
been defined in diet induced-obesity and metabolic syndrome models 187,189,190,236. The 
CB1 receptor knockout mice are resistant to diet-induced-obesity 237,238. Selective 
reduction in CB1 receptor expression in the colon of germ free mice, Myd88(-/-) mice, 
TRIF (-/-) mice, probiotic and antibiotic treated-obese mice, can attributed to altered gut 
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microbial composition 183,239,240,241. Myd88 and TRIF are the integral adaptor molecules 
of toll-like receptor (TLR) signaling pathway which mediates the microbial community-
host interactions 242. Alteration in gut microbial community following blockade of 
cannabinoid CB1 receptor in DIO model has not been previously studied.  Thus, the 
current study, demonstrated for the first time that the protective effect of a CB1 receptor 
antagonist in diet induced-obesity may result from dysbiosis of gut microbiota.   
Previous studies demonstrated significant reduction in Akkermansia muciniphila 
in both genetically ob/ob and diet-induced-obese mice 243,244. Protective properties of 
dietary polyphenols and probiotics in obese and diabetic phenotypes has been attributed 
to the restoration of the abundance of this strain in gut 245,246,247. Recent study identified 
the protective effect of orally transferred A.muciniphila in dextran sulfate sodium (DSS)-
induced colitis model 248. Furthermore, adoptive transfer of live A.muciniphila but not the 
heat-killed cells was shown to ameliorate obese and diabetic phenotypes, reduce 
metabolic endotoxemia, host adiposity, and improve glucose metabolism 218,222,249.  In the 
present study, we demonstrated that the resorted abundance of A.muciniphila in DIO 
mice following blockade of CB1 receptor was independent of calorie restriction and 
weight loss. To further confirm the therapeutic effect of CB1 receptor antagonist in DIO 
model, we investigated the direct effect of SR141716A treatment on the colon physiology 
in the host. We demonstrated significant improvement in MUC2 and KLF4 genes in 
colon of the SR141716A-treated obese mice when compared to the vehicle-treated obese 
mice. The transcription factors KLF4 and MUC2 regulate differentiation of goblet cells 
which is associated with mucin formation in colon 250. Our data suggested that 
A.muciniphila is responding to increased host mucin production following blockade of 
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cannabinoid CB1 receptor in DIO mice, and mucin serves as the main of carbon, 
nitrogen, and sulfur for A.muciniphila growth.  
Furthermore, we conducted gas chromatography to address the changes in short 
chain fatty acid of cecal material. Blockade of cannabinoid CB1 receptor caused more 
production of propionate and butyric acid in cecal material. Previous studies identified 
the regulatory mechanism of propionate and butyrate in glucose homeostasis, lipid and 
cholesterol metabolism, and improvement of gut barrier function, supporting the 
beneficial regulatory effect of SR141716A on the metabolic parameters in obese 
individuals 251. The anti-inflammatory properties of propionate (suppression of pro-
inflammatory M1 macrophages), and butyrate (inhibition of inflammation via NF-κB 
pathway) has been established earlier 252,253). Consistent with our data, earlier research 
defined propionate as the A.muciniphila metabolite 244,254. Recent study elucidated the 
protective effect of propionate and butyrate against diet-induced obesity complications 
and metabolic syndrome. Propionate and butyrate SCFA have been identified to suppress 
appetite actively by modulating the gut hormones such as Peptide YY (PYY), and 
Glucagon-Like Peptide-1 (GLP-1)  222,255. The excessive release of GLP-1 and PYY into 
portal vein was identified following propionate infusion into the murine colon. 
Additionally, higher activity of entroendocrine L-cells (GLP-1, and GLP-2 secretion) was 
identified with the growth of Akkermansia muciniphila, and further investigation is 
needed to uncover the mechanism underlying this connection 183,218.  However, whether 
the primary beneficial effect of SR141716A can be attributed to the gut abundance of 
A.muciniphila or higher activity of L-cells in DIO remains an interesting question that 
warrants further investigations. 
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In conclusion, the current study suggests that the underlying mechanisms through 
which SR141716A, a CB1 antagonist, exerts its protective effect against diet induced-
metabolic dysfunction may involve changes in the gut microbial community with an 
increase in A. muciniphila and a decrease in immunogenic Lanchnospiraceae and 
Erysipelotrichaceae.  Indeed, the direct application of A.muciniphila as the therapeutic 
intervention remains elusive because of its anaerobic growth condition. Therefore, 
therapeutic intervention strategies aimed at growth of A.muciniphila, will likely be an 
interesting tool for combating the global burden of obesity and metabolic syndrome.  
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Figure 3.1 SR141716A causes transient reduction in diet intake and persistent 
weight loss as compared with Vehicle-treated DIO control.  (A) DIO model was 
generated by feeding C57BL/6J male mice with high-fat diet (HFD+Vehicle) whereas 
their lean, age-matched controls were fed low-fat diet (LFD+Vehicle). HFD-fed mice 
were treated with either SR141716A (10mg/kg/day) (HFD+SR) or vehicle (0.1% Tween 
80) (HFD+Vehicle) by daily oral gavage for 4 weeks starting at week 12.  In order to 
assess the anti-inflammatory effect of SR141716A beyond its effect on calorie intake 
inhibition and weight loss in DIO phenotype, pair-feeding was conducted in diet-intake 
matched controls (PFSR) and diet intake was adjusted in body-weight-matched controls 
(BWM).; n=8-10 mice/group. (B) Daily energy intake during 4 weeks’ treatment with 
SR141716A in DIO mice was recorded, Area Under the Curve (AUC) was calculated 
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from the 5 replicated experiments (C) Daily body weight of each group of mice is shown 
during the whole period of treatment, Area Under the Curve (AUC) was calculated from 
the 5 replicated experiments which were identical to the replicates in Figure 1b. AUC 
was calculated with Trapezoidal rule in R software. Generalized Estimating Equation 
(GEE) was performed to fit a repeated measurement logistic regression in SPSS. Data are 
shown as as means ± SD. Data with different superscript letters are significantly different 
(P < 0.05). (D)Pearson correlation between changes in body weight and caloric intake 
within different groups was assessed in R software. (E)Total fat mass gain and changes in 
lean mass was assessed at the baseline and after 4 weeks of treatment with Dual Energy 
X-ray absorptiometry (DEXA).Data are shown as as means ± SD. Data with different 
superscript letters are significantly different (P < 0.05).(F) The surface area of 100 
adipocytes was determined  and then averaged to represent mean adipocyte size for each 
mouse using ImageJ software,NIH. Data are shown as means ± SD. Data with different 
superscript letters are significantly different (P<0.05) according to post hoc ANOVA 
one-way statistical analysis. (n=10) (G) Weights of fat pads and livers were  assessed at 
the end of the treatment. After treatment for 4 weeks, HFD+SR  group had lower body 
weight, smaller fat pads and livers than HFD+Vihcle group. Smaller fat pads and lower 
body weight was recorded in HFD+SR group than HFD Pair-fed  to SR141716A( PFSR), 
although both groups had the same quantity of high fat diet intake. The HFD+SR group 
has a smaller fat pad than Body weight Matched (BWM) group. Overall data is 
suggesting the effect of SR141716A treatment is beyond its effect on weight loss and diet 
intake 
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Figure 3.2 SR141716A attenuates local and systematic inflammation in diet-induced 
obesity phenotype. (A)Adipose Tissue Macrophages (ATMS) were quantified per 100 
adipocytes by Spot Studio v1.0 Analysis Software. (B,C)Kidney fat were isolated from 
10 mice in each group. The ratio and total cell number of kidney fat F4/80 and CD11c 
cells was decreased with SR141716A treatment (33.3%) when compared to 
HFD+Vehicle (82.4%) (D) Effect of SR141716A on the plasma IL-17 levels, (E) 
monocyte chemoattractant protein-1(MCP-1) levels, (F) Eotaxin plasma levels, and (G) 
macrophage inflammatory protien-1𝛂 (MIP-1𝛂) level in plasma was quantified with 
multiplex detection immunoassays. SR141716A-treated DIO mice(HFD+SR) have 
significantly lower systematic inflammation (as compared to vehicle-treated DIO 
mice(HFD+Vehicle), and Pair-fed to SR141716A controls(PFSR). (H) Plasma LPS level 
in DIO mice treated with SR141716A for four weeks and controls was quantified (I) 
Effect of SR141716A treatment on the mRNA level of RORᵧ (J)TNF-𝛼 (K) iNOS (l) IL-6 
in the epididymal adipose tissue was examined. (M) Myeloperoxidase (MPO) level in 
colonic tissue was measured. Data are shown as means ± SD. Data with different 
superscript letters are significantly different (P<0.05) according to post hoc ANOVA 
one-way statistical analysis. (n=5 except LFD+Vehicle n=4) 
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Figure 3.3 SR141716A ameliorates metabolic dysfunction in diet-induced obesity 
phenotype. (A) Glucose tolerance test(GTT) and (B)Insulin tolerance test (ITT) of mice 
fed LFD+Vehicle (n=10), HFD+Vehicle (n=10), HFD+SR (n=9) and Pair-fed to 
SR141716A (PFSR) (n=10). Each animal received a glucose gavage 1.5g/KG body mass 
of glucose (25% D glucose) Blood glucose levels were determined after 15,30,60 and 120 
minutes. Insulin-tolerance tests were carried out on un-fasted animals by injecting an i.p 
injection of 1.5 U/Kg body mass of insulin. Blood glucose levels were detected after 15, 
30,60 and 120 minutes. Generalized Linear Mixed Model (GLMM) was performed to 
calculate p values for the repeated measures in SPSS. Mean area under the curve (AUC) 
from triplicate experiments measured between 0-120 minutes after glucose (GTT) and 
insulin (ITT) load. AUC was assessed with Trapezoidal rule in R software. Data with 
different superscript letters are significantly different. GTT (P<0.01), ITT (P<0.05). 
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Figure 3.4 SR141716A restores gut barrier function in diet-induced obesity 
phenotype. (A) Representative Periodic Acid Schiff images that were used for in situ 
mucus layer staining, scale bar,100 µm. (B)Thickness of the mucus layer measured by 
histological image analysis software MetaMorph (LFD+Vehicle n=5, HFD+Vehicle n=5, 
SR n=6, PFSR n=5, and BWM n=6). (C-E) mRNA expression analysis by qRT-PCR of 
mucus-related genes in the colonic mucosa. (F)Intestinal permeability measured by levels 
of serum FITC-Dextran (4kDa) following oral gavage (n=5 except LFD+Vehicle n=4). 
Data are shown as means ± SD. Data with different superscript letters are significantly 
different (P<0.05) according to post hoc ANOVA one-way statistical analysis.  
 
 
 
                                                                                                                  Figure 3.5 
Figure 3.5 SR141716A attenuates over-activity of endocannabinoids system in diet-
induced obesity phenotype. (A)Adipose tissue CB1 mRNA levels in SR141716A-
treated DIO, (HFD+SR), vehicle-treated DIO (HFD+Vehicle), lean mice (LFD+Vehicle) 
and Pair-fed to SR141716A (PFSR) controls mice was assessed by RT-PCR.  (B)White 
adipose tissue AEA level from the same mice (percent of control values) were measured 
with LC/MS/MS (n=3). AEA levels (percent of LFD+Vehicle) in the epididymal adipose 
tissue of HFD+SR, HFD+Vehicle and PFSR(n=3). Data are shown as means ± SD. Data 
with different superscript letters are significantly different (P<0.05) according to post hoc 
ANOVA one-way statistical analysis. 
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Figure 3.6 SR141716A improves adipose tissue metabolism in 
diet-induced obesity phenotype. (A)mRNA expression of markers of adipocyte 
differentiation (C/EBPα,PPARγ), (B) lipogenesis (ACC1; FASN), (C) and lipid oxidation 
(CPT1; ACOX1; PGC-1α; and PPARα) was measured in epididymal fat depots (n = 5). 
Data are shown as means ± SD. Data with different superscript letters are significantly 
different (P < 0.05) according to post hoc ANOVA one-way statistical analysis.  
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Figure 3.7 SR141716A alters gut microbiota in diet-induced obesity phenotype. 
Metagenomics analysis were performed on 16S rRNA V3+V4region data, rarefied to a 
depth of 10,000 reads per sample. (A)Beta-diversity of the gut microbiome was evaluated 
by weighted UniFrac-based principle co-ordinates algorithim. The analysis was 
performed using the abundance matrix of genus-level OTUs in different samples, and 
pairwise community distances were determined with .97 similarity using the weighted 
UniFrac algorithm.  Exceptions from study groups were observed. (B)Species richness 
metric based on Chao1 method was calculated. (C) Relative taxa abundance area plots for 
individuals from the five populations, summarized at the genus level. Individuals are 
represented along the horizontal axis, and relative taxa frequency is denoted by the 
vertical axis. (D)A. muciniphila (E) Lanchnospiraceae, (F) and Erysipelotrichaceae 
abundance (log10 of bacteria per g of fecal content) measured in the fecal content of mice 
(n = 10). Values with different superscript letters are significantly different, (P<0.01) 
according to post hoc ANOVA one-way statistical analysis.  
D E 
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Figure 3.8 SR141716A treatment changes gut 
microbiome and its SCFAs metabolites which 
mimics anti-inflammatory status in diet-induced obesity phenotype. (A-B) Gas 
chromatography with flame Ionization Detector(GC-FID) quantification of SCFA levels 
in the cecal and fecal contents. Representative data are from triplicate experiments. 
Vertical bars represent mean ± SD. ANOVA/Tukey *p < 0.05; **p < 0.01; ***p < 0.001  
* 
A 
B 
Figure 3.8 
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Supplementary Figure 3.1 SR1417161A significantly reduced the interstitial fibrosis 
of adipose tissue in diet-induced obesity phenotype. (A)Representative picrosirius red 
images that were used for quantification of fibrosis area in adipose tissue of individuals 
(LFD+Vehicle n=6, HFD+Vehicle n=10, SR n=9, and PFSR n=7). (B)The percentage 
area for picrosirius red-positive was quantified by converting the image to RGB (Red, 
Green, Blue) stack image and setting the lower and upper threshold values into the 
feature of interest and background in Image J software, NIH.  Data are shown as means ± 
SD. Data with different superscript letters are significantly different (P<0.05) according 
to post hoc ANOVA one-way statistical analysis.  
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Supplementary Figure 3.2 SR141716A improves anti-inflammatory Th2 subset and 
Myeloid Derived Suppressive Cells (MDSCs) in diet-induced obesity phenotype. 
(A,B)Kidney fat was isolated from 10 mice in each group. The ratio and total cell number 
of Gata-3+ CD4+ cells (Th2) in stromal vascular fraction of kidney fat was increased 
with SR141716A treatment in DIO mice (HFD+SR) (13.8%) when compared to vehicle-
treated DIO mice HFD+Vehicle (4.7%). (C,D) The ratio and total cell number of   GR-1+ 
and CD11b+ cells (MDSC) in stromal vascular fraction of kidney fat were increased with 
SR141716A treatment in DIO mice (HFD+SR) (35.7%) when compared to  vehicle-
treated DIO mice (HFD+Vehicle)(18.6%) Data are shown as means ± SD. Data with 
different superscript letters are significantly different (P<0.05) according to post hoc 
ANOVA one-way statistical analysis. (E) The ratio of MDSC was assessed by flow 
cytometry in blood from different groups. The percentage of circulating GR-1+ and 
CD11b+ cells (MDSC) were decreased with SR141716A treatment in DIO mice (10.2%) 
when compared to vehicle-treated DIO HFD+Vehicle mice (18.2%). 
 
 
Table 3.1 SR141716A treatment improves the impaired CBC in diet-induced obesity 
phenotype. Whole blood was collected from posterior vena cava and subjected to the 
differential hematological analyzer. (LFD+Vehicle n=8, HFD+Vehicle n=9, HFD+SR 
n=10, and PFSR n=6). Data are shown as means ± SD. Unpaired- Ttest was performed 
between HFD+SR and HFD+Vehicle group. Statistical significance was set as value of 
*p < 0.05. 
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Table 3.2 SR141716A treatment improves the impaired metabolic parameters in 
diet-induced obesity phenotype. Plasma was assessed for fasting (5 hr) concentrations 
of glucose, insulin, total cholesterol (TC), HDL-C, LDL-C, and triglycerides prior to the 
SR141617A treatment at week 12 of diet and at the end of the SR141716A treatment 
course at week 16. Insulin resistance was estimated by HOMA index as follows: insulin 
resistance index  =  fasting insulin (µU/ml) x fasting glucose (mmol/l)/22.5 
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Supplementary figure 3.3 SR141716A treatment reversed the increase in Free Fatty 
Acids in diet-induced obesity phenotype.  FFA concentrations were measured in serum. 
Data represent means ± SD from (LFD+Vehicle n=5, HFD+Vehicle n=5, SR n=6, PFSR 
n=5, and BWM n=6). Data with different superscript letters are significantly different 
(P<0.05) according to post hoc ANOVA one-way statistical analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3.3 
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Table 3.3 Composition of Chimeras and Operational Taxonomical Units (OTUs) in 
16srRNA sequencing. The percentage of the chimeras in each fastq files of individual 
samples and total counts of OTUs was obtained from Qiime software. Number of 
samples: 25, Number of observations: 17245, Total count: 8220204, Table density 
(fraction of non-zero values): 0.219 ,Min counts: 220662.0, Max counts: 601577.0, 
Median of counts: 308574.000, Mean of counts: 328808.160 with Std. dev.:79010.459 
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Supplementary Figure3.4 SR141716A treatment alters Short Chain Fatty Acids 
(SCFAs) systematically. Gas chromatography with flame Ionization Detector(GC-FID) 
quantification of SCFA levels in serum. Representative data are from triplicate 
experiments. Vertical bars represent mean ± SD. ANOVA/Tukey *p < 0.05; **p < 0.01; 
***p < 0.001  
 
 
Table 3.4 Primers sequences. The forward and reverse sequences of each primer in the 
current study is provided. 
 
 
Supplementary Figure 3.4 
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CHAPTER IV: ROLE OF MICRORNA IN THE REGULATION OF NETRIN-1-
MEDIATED MACROPHAGE MIGRATION AND POLARIZATION IN 
ADIPOSE TISSUE THROUGH AGAP-2 INTERACTION WITH UNC5B 
 
 
4.1 INTRODUCTION 
 
The growing incidence of obesity in the last 25 years defines it as an epidemic; 
with estimates upwards of 1.45 billion overweight adults in the world, of which 
approximately 500 million are obese256. Moreover, a maintenance of childhood obesity at 
16% prevalence from 2006-2010 and a significant increase in obesity prevalence over a 
12 year period in males aged 2-19 years was observed257.  
Chronic low-grade, systematic inflammation associated with obesity plays a 
major role in the development of various chronic disease states, including type 2 diabetes, 
metabolic syndrome and atherosclerotic cardiovascular disease which contribute to high 
rates of mortality and morbidity258.  Stromovascular fraction of adipose tissue is 
aggregated with immune cells during obesity259. In particular, with intense migration of 
Macrophages (Mɸ) in adipose tissue, Adipose Tissue Macrophages (ATMs) have been 
shown to be integral to the obesity-triggered inflammation in adipose tissue 260,261,262,  and 
their recruitment to adipose tissue correlates with the production of  pro-inflammatory 
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molecules , including tumor necrosis factor-α (TNF-α)263, interleukin-1β (IL-1β) and IL-6 
264,265 that potentiate insulin resistance 266. Macrophages are phagocytic cells which show 
incredible heterogeneity in phenotype and function, as local milieu factors determine 
their activation state and subsequent properties. Mɸs are thought to be activated in two 
separate pathways becoming polarized to M1 or M2 states. With over-nutrition, M1 are 
said to be “classically activated” mɸs induced by LPS and IFNγ that secrete pro-
inflammatory cytokines (TNF-α, IL-6, IL-12) and generate nitric oxide (NO, a reactive 
oxygen species) via iNOS activation267, 268. However, “alternatively activated” mɸs or 
M2 that populate lean adipose tissue are activated by IL-4 and IL-13, secrete anti-
inflammatory cytokines, and have upregulated arginase which opposes NO production269. 
However, studies have shown that the M1 and M2 macrophage phenotypes are not 
clearly defined, the key signaling molecules such as DNA methyltransferase 3b 
(DNMT3b) and peroxisome proliferator activated receptor-γ(PPAR-γ) deregulate ATMs 
polarization, inflammation and insulin insensitivity270,271. In addition, other studies have 
shown that besides the molecules which trigger the macrophages recruitment in adipose 
tissue, other signaling molecules such as neural guidance cue (semaphorin, ephrin and 
netrin families) modulate macrophages retention in adipose tissue and regulate 
immunometabolism272, 273,274. Indeed, a recent study showed inhibition of semaphorin 3E 
in the visceral adipose tissue of DIO mice resulted in a significant improvement in 
adipose tissue inflammation and subsequently insulin resistance in this model275. 
Collectively, studies on neuronal guidance cue in ATMs define them as key regulators for 
macrophages accumulation in adipose tissue in regard to chronic inflammation of VAT. 
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Weight loss is associated with beneficial effects on reducing the underlying 
inflammation in adipose tissue and subsequently ameliorates insulin insensitivity276, 277. 
Endocannabinoid system plays a major role in diet intake and energy balance. Over-
activity of endocannabinoid system in human obesity and in animal models of genetic 
and diet-induced obesity has been reported278.  Clinical studies on treatment of obesity 
and metabolic syndrome with cannabinoid CB1 receptors antagonist have shown greater 
weight loss in obese patients compared with placebo 279. Nevertheless, the mechanistic 
effect of CB1 receptor antagonist on inflammation and ATMs has not been well studied.  
Previous studies have shown that blockade of CB1 receptors suppressed inflammation in 
adipose tissue of DIO mice250, 251. The signals controlling the beneficiary effect of the 
CB1 receptor antagonists on inflammation in the adipose tissue remain poorly 
understood, but are likely involve reduced recruitment, local macrophage death and 
egress of macrophage from the inflammatory site.  
In the present study, utilizing a mouse model of diet- induced obesity, we uncover 
a key role for SR141716A, a CB1 receptor antagonist, in the retention of macrophages in 
the visceral adipose tissue during obesity by triggering neuroimmune guidance cue 
netrin-1 and its receptor Unc5b.Here we show that Netrin-1 and its receptor Unc5b in 
ATMs are markedly suppressed upon SR141716A treatment in DIO mice, and investigate 
the effect of SR141716A beyond its effect on weight loss and diet intake by conducting 
the pair-fed group and body weight matched control to the SR141716A treated group. 
Our data demonstrates that SR141716A suppressed diet intake transiently, however 
weight loss and reduction in fat mass was persistent and consequently the effect of CB1 
receptor blockade on inflammation is independent of its effect on weight loss and diet 
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intake. Suppression of pro-inflammatory macrophages was observed in SR141716A-
treated HFD-fed group followed by down regulation of Netrin-1 and Unc5b in 
macrophages, which results in egression of ATMs from inflammatory adipose tissue, and 
subsequently improvement of insulin resistance and glucose impaired metabolism.  
 
4.2 MATERIALS AND METHODS 
Animals.  
16-18 weeks old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) 
were fed a HFD consisting of 60% Kcal from fat (Research Diets Incs,New Brunswick, 
NJ) or the control age matched fed a LFD consisting of 10% Kcal from fat (Research 
Diets Incs, New Brunswick, NJ). SR141716A was obtained from NIDA and administered 
10µg/kg daily oral gavage in .01% Tween 80 in DI water. All mice were maintained in 
the pathogen free at the AAALAC-accredited animal facility at the University of South 
Carolina, School of Medicine (Columbia, SC).  All procedures were performed according 
to NIH guidelines under protocols approved by the Institutional Animal Care and Use 
Committee. 
 
Analytical procedures. 
The fat content in the mice was analyzed by dual-energy X-ray absorptiometry 
(DEXA, LUNAR, Madison, WI) scanning. The mice were anesthetized and placed in the 
prone position on the specimen tray to allow scanning of the entire body. For food intake 
measurements, mice were given a defined amount of large intact food pellet weekly. 
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Food weight was measured using a balance with a precision of 0.01 g , and cages were 
changed. Solid food intake was corrected for any visible spillage 282  
 
Metabolic parameters assessment  
Fasting concentrations of glucose, insulin, total cholesterol, and triglycerides was 
assessed at the baseline and day 27 (prior to sacrificing day). Animals were fasted for 5 
hours and blood were collected from the tip of the tail. The glucose level in whole blood 
was measured with glucometer (Bayer Contour, MiChawaka, IN). Insulin concentration 
was determined in isolated plasma using Elisa kit (abcam, Cambridge, MA). Total 
cholesterol (Genzyme, Kent, United Kingdom), and triglycerides (Pointe Scientific, 
Canton, Michigan) were determined according to the manufacturer. HOMA index was 
calculated for insulin resistance as previously described 283.  
 
Tissue collection 
After 4 weeks of treatment, mice were sacrificed for tissue collection. Tissues 
were removed, weighed, and immediately snap-frozen in liquid nitrogen and stored at 
−80°C or fixed in 10% formalin until analysis. 
 
Adipocyte and adipose tissue macrophage purification. 
Epididymal fat pads of mice were excised and placed in gentleMACS C Tubes 
(MACS Miltenyi Biotec, San Diego, CA) containing digestion medium (HSBSS,2mg/ml 
collagenase (Sigma-Aldrich, St. Louis, MO) and 2% BSA, and followed to be 
homogenized by utilizing gentleMACS Dissociator (MACS Miltenyi Biotec, San Diego, 
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CA). After incubation at 37 °C for 30 min with shaking, the cell suspension was filtered 
through a 100-µm filter and then spun at 300g for 5 min to separate floating adipocytes 
from the Stromal Vascular fraction (SVF) pellet. Isolation of F4/80 cells from SVF 
isolates was performed by magnetic immunoaffinity isolation with anti-F40/80 antibodies 
conjugated to magnetic beads (10 µl per 1 × 107 cells, EasySep™ FITC Positive 
Selection Kit, Stem Cells Technologies, Vancouver, BC). Cells were isolated using 
positive selection columns before preparation of whole-cell lysates. 
 
Real-time Quantitative RT-PCR Analysis  
RNA (0.5–1 µg) was reverse-transcribed using miScript cDNA Synthesis Kit 
(Qiagen, Valencia, CA), and RT-PCR analysis was conducted using SsoAdvanced™ 
Universal SYBR® Green Supermix kit (Bio-Rad,Hercules, CA) . The primers used are 
listed in Supplementary Table 4. Fold change in mRNA expression was calculated using 
the comparative cycle method (2−ΔΔCt).  
 
Gene expression profiling. 
1 mg of adipose tissue from either lean or obese animals was homogenized in 
RNA-Solv Reagent with OBI’s innovative HiBind® technology reagent (Omega Bio-tek, 
Norcross, GA)) and total RNA isolated as we previously described283. RNA quality was 
verified by NanoDrop 2000C (Thermo Scientific, Waltham, MA). Adipose tissue RNA 
(0.5-1 µg) was reverse-transcribed, and quantitative RT-PCR analysis of the four families 
of the axonal guidance molecules, macrophages markers (iNOS, ARG-1) was performed. 
Data analysis was performed using ΔΔCt-based fold change calculations. 
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miRs expression profiling and analysis.  
The unique expression profile of miR assessed in F4/80 cells isolated from 
adipose tissue by Affymetrix GeneChip miRNA 3.0 array platform. The array contains 
3100 murine-specific probes from Sanger miRBase. Total RNA were 3′-end labeled with 
FlashTag biotin HSR hybridization technique (Genisphere, Hatfield, PA) and was carried 
out according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). 
Correlation of the hybridization signal intensities of all the expressed miRs were log 
transformed and visualized in the form of a heatmap.  Ward’s method was assessed for 
hierarchical clustering of differentially expressed miRs. miRs QC Tool (Affymetrix Inc), 
a software for data summarization, Log2 transformation, normalization and quality 
control, was used as described previously 284 . 
 
Bioinformatics analysis.   
The differentially expressed miRs’ target genes were assessed by miR target 
prediction algorithms miRwalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/), 
miRmap  (http://mirmap.ezlab.org).To carry out an enrichment analysis of predicted 
target genes of miRs in biological pathways, the commercially available analysis tool 
Ingenuity Pathway analysis (IPA), (Mountain View, CA, USA.), was used. IPA predicts 
the top affected Canonical Pathways, causal connections between differentially changed 
miRs and their target genes, downstream effect along with their upstream regulators. The 
Molecular Activity Predictor (MAP) feature of IPA was performed to predict the 
downstream effect of the differentially expressed miRs which were overlaid to the dataset 
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including miRs probes, fold changes and the p Values. Gene ontology was assessed in 
Cytoscape platform using CluGo app 285.  
 
 
ELISA assays. 
Netrin-1 (USCN Life science, Houston, TX) levels were measured in the serum or 
cell supernatants using mouse standards according to manufacturer's guidelines.  
 
 
Migration. 
The migration of macrophages to CCL19 (500 ng/ml, R&D Systems) was 
assessed by FluroBlok permeable inserts (Corning, Tewksbury, MA) and Cytation5 
imaging (BioTek, Winooski, VT). Peritoneal macrophages were harvested from the 
primed mice with 1ml of 3% (wt/vol) thioglycolate to elicit peritoneal exudates with 
macrophage number peaking on day 4. Inter-peritoneal wash performed to collect 
macrophages. For tracking macrophage migration towards chemoattractants, 
macrophages were labeled with DiIC12(3) Fluorescent Dye (Corning, Tewksbury,MA). 
Macrophages were treated with conditioned media from 3T3-L1 adipocytes differentiated 
as described 286. Then later, Macrophages were treated either with SR141716A (10-6 M) 
or DMSO as the vehicle 287.  
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Western blot analysis. 
Western blot analyses were carried out according to standard protocols with 
antibodies raised against netrin-1 (R&D Systems, Minneapolis, MN), γ-tubulin (Sigma-
Aldrich, St. Louis, MO) was used as loading control. 
 
Molecular docking   
 
The structure of the Rimonabant (SR141716A) (Compound ID: 104850) 
compound was downloaded from the Pubchem compound database, an open repository 
for small molecules and their respective experimental biological activity 288. The 3D 
coordinates of the X-ray Crystal Structure of Mouse Netrin-1(PDB ID: 4OVE) 289 for 
Netrin-1 and the crystal structure of the UNC5H2 death domain (PDB ID: 1WMG) 300 for 
UNC5B were retrieved from the Protein data bank [5]. Molecular docking was performed 
using the Autodock 4.2 301. Structures were analyzed using PyMOL (PyMOL Molecular 
Graphics System, Version 1.7.4.5 Schrödinger, LLC).  
 
Transfection and reporter gene assay. 
 
Bone Marrow Derived Macrophages (BMDM) were transfected with a plasmid 
with a Renilla luciferase (transfection efficiency control) and 3’UTR AGAP-2 (Gene 
Accession: NM_001301014.1UTR Length:  808 bp ( -383 - 787 bp ) ) of a Firefly 
luciferase reporter gene. Cloning details was as follow: the whole plasmid size:7097, 
Vector: Pezx-MT06, Promoter: SV40, Antibiotic Ampicillin, 5' Cutting Site:   AsiSI, 
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EcoRI, BsiWI3' , Cutting Site :   XhoI,SpeI with sequencing Primers Forward:  5'-
GATCCGCGAGATCCTGAT-3' Reverse:  5'-CCTATTGGCGTTACTATG-3' 
(GeneCopeia TM , Rockville, MD). Firefly luciferase expression is therefore suppressed 
by the corresponding endogenous miR level in the cell. The day after the cell cultures 
were transfected with miR-762 miRCURY LNA™ microRNA Inhibitor(5nM) (Exiqon, 
Woburn, MA).  Lipofectamine® RNAiMAX Transfection Reagent (ThermoFisher 
Scientific, Waltham, MA) was used for delivery of oligos into the cell.   
 
Statistical Analysis.  
 
  For the in vivo mouse experiments, 10 mice were used per experimental group, 
unless otherwise specified. For in vitro assays, all experiments were performed in 
triplicate. Body weight, body composition outcomes, and metabolic outcomes were 
analyzed using a repeated measures two-way ANOVA. For statistical differences, one-
way ANOVA was calculated for each experiment.  Tukey’s post-hoc test was performed 
to analyze differences between groups.  A p value of ≤ 0.05 was considered statistically 
significant. 
 
4.3 RESULTS 
 
SR141716A Effect on body weight, calorie intake, and body composition 
In consistent with previous studies, blockade of cannabionoid  CB1 receptors with 
SR141716A resulted in transient reduction of calorie intake and persistent weight loss in 
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diet-induced obesity mice(Fig 4.1A, 4.1B) 293,294.  The acute reduction in calorie intake 
with SR141716A treatment in DIO phenotype was diminished by day 9 of treatment. The 
average of daily calorie intake in HFD+SR group became close to the average of daily 
calorie intake of HFD+Vehicle group through the end of the study (Fig 4.1C). 
Interestingly, the weight loss with SR141716A treatment in DIO phenotype (HFD+SR) 
was sustainable regardless of markedly high calorie intake.  In order to examine the effect 
of SR141716A beyond its effect on diet intake, pair-feeding was performed in pair-fed to 
SR141716A (PFSR) group 295. The diet intake was restricted in PFSR group to the 
amount of daily diet intake of HFD+SR group.  
At the baseline of study, the mice were normalized and grouped based on the fat 
mass composition. After 4 weeks of treatment the body composition was assessed. 
Reduction in the fat mass and fat percentage was significant in HFD+SR group in 
compare to both HFD+Vehicle and PFSR groups, while the changes in lean mass was 
ignorable (Table 4.1). Taken together, our data suggested that blocked of cannabinoid 
CB1 receptors in DIO phenotype resulted in amelioration of obesity independent of its 
effect on calorie intake. 
 
 
SR141716A effect on metabolic profile  
Fasting blood glucose, Insulin, insulin resistant index (HOMAindex), cholesterol 
and Triglycerides was examined at the baseline and prior to the sac day on (Day 27). Our 
data demonstrated improvement in metabolic parameters of DIO mice with SR141716A 
intervention treatment (HFD+SR) in compare to vehicle-treated DIO mice 
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(HFD+Vehicle) (Fig 4.2A-4.2E). The remarkable improvement in metabolic profile in 
SR141716A treated-DIO mice (HFD+SR) in compare to the pair-fed (PFSR) group was 
the proof of independent effect of SR141716A treatment from its effect on calorie intake.  
 
 
Effect of SR141716A on adipose tissue macrophages and their microRNA profile 
In order to study the anti-inflammatory effect of cannabinoid CB1 receptor 
antagonist on adipose tissue, we examined the M1 (pro-inflammatory) and M2 (Anti-
inflammatory) macrophages profile. The lower iNOS expression along with the higher 
expression of Arg-1 induced the anti-inflammatory state in adipose tissue of DIO mice 
following SR141716A intervention treatment.  Previously we have assessed the 
comprehensive cytokinesis both systematically and locally in DIO phenotype following 
treatment with SR141716A.  Our study demonstrated the shift from M1 macrophages to 
the anti-inflammatory M2 macrophages following SR141716A treatment. Induction of 
anti-inflammatory state in SR141716A-treated DIO mice was constant in our study. In 
order to a have better understanding in underlying mechanism in attenuation of 
inflammation, we performed high throughput analysis of microRNA profile in adipose 
tissue macrophages.   
For the first time we isolated the total RNA from the infiltrated macrophages in 
adipose tissue. The F4/80 cells were isolated from the stromal vascular fraction of 
adipose tissue in different groups of the study. The heatmap from the microRNA (miR) 
microarray expression data revealed noticeable differences in fold change intensities 
between the different groups (Fig 4.3A).  Approximately 5.7% of miRs were either over-
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expressed (36) or under-expressed (141) greater than or equal to 2 fold-change following 
SR141716A treatment in DIO (HFD+SR) group in compare to vehicle-treated DIO 
(HFD+Vehicle) group, while 6.09% of miRs were significantly changed in SR141716A-
treated DIO (HFD+SR) group in compare to its pair-fed (PFSR) group (164 up-regulated, 
25 down-regulated) (Fig 4.3B,4.3C).  
On further analysis we identified the targeted gene ontology of dysregulated miRs 
using Cytoscape analysis module. Regulation of immune system processes was the main 
effected pathway following SR141716A treatment in DIO phenotype (Fig 4.3D). To have 
a better understanding, we performed further analysis using Ingenuity Systems IPA. The 
interaction between miRs and their targeted gene following SR141716A treatment in 
DIO phenotype demonstrated distinctive changes in the miR profile which skews the 
adipose tissue macrophage balance to more anti-inflammatory macrophages 
(M2,Arginase +) (Fig 4.3E) 
 
Independent effect of SR141716A from diet restriction on miR profile 
In order to investigate the effect of SR141716A on miR profile independent of its 
effect on calorie restriction, the overlaid of the altered miR following SR141716A with 
altered miR in pair-fed group were selected. Dual color bar graph and Pearson correlation 
of altered miR in SR+HFD group (Log2 fold change of HFD+SR in comparison with 
HFD+Vehicle) and  PFSR group (Log2 fold change of HFD+SR in comparison with 
PFSR), summarized the selected altered miR in HFD+SR group independent of its effect 
on diet restriction (Fig 4.4A,4.4B). Interestingly, we uncovered the novel role of the 
altered miR in induction of anti-inflammatory M2 macrophages by targeting the M2 
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related transcription factors (STAT3, STAT6, LCN2, KLF4, PPARg, SIRT1) using 
Ingenuity Systems IPA (Fig 4.4C). The list of corresponding targets and miR, along with 
their algorithm has been summarized (Table 4.2). More interestingly, for the first time we 
uncovered that most of the miR members of miR-466 family has been down-regulated 
following SR141716A treatment regardless of calorie intake. miR-466 family mimic anti-
inflammatory state in adipose tissue by targeting the anti-inflammatory M2 macrophages 
transcription factors such as KLF4, and STAT6.  RT-PCR for miR-466 family from the 
ATMs validated their down-regulation following SR141716A treatment (Supplementary 
fig 4.1A).  
 In order to validate the effect of miR-466 family in induction of M2 phenotype in 
ATMs, peritoneal macrophages were isolated following thyogicolate ip. injection. 
Macrophages were then cultured in conditioned media from differentiated 3T3-L1cells to 
adipocytes following transfection with miR-466i and miR-466f LNA TM power  
inhibitors. KLF4 and STAT6, the transcription factors of M2 macrophages, were 
significantly over-expressed following miR-466 inhibition (Supplementary Fif 4.1B). 
Thus, intervention treatment of DIO mice with SR141716A (Cannabinoid CB1 receptor 
antagonist) potentially restore the balance of M1 and M2 macrophages in adipose tissue. 
 
SR141716A ameliorates ATM retention in adipose tissue 
 The recent studies demonstrated the potential role of the neuroimmune guidance 
cue Netrin-1 in promoting the defective migration of ATMs in obese phenotype 274. 
Higher expression of Netrin-1 in ATMs of obese phenotype, and its interaction with 
Unc5b receptor resulted in ATMs retention in adipose tissue and subsequently chronic 
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inflammation followed by insulin resistance.  Previously we demonstrated the significant 
less frequency and number of pro-inflammatory M1 macrophages in adipose tissue of 
HFD+SR treated group in compare to HFD+Vehicle group. Interestingly, we uncovered 
the unknown effect of SR141716A in attenuation of chronic inflammation in adipose 
tissue, by effecting Netrin-1 and its receptor Unc5b in ATMs. The level expression of 
Netrin-1 at both protein and transcription level was significantly reduced following 
SR141716A treatment in DIO (HFD+SR) mice in compare to vehicle-treated DIO 
(HFD+Vehicle) mice (Fig 4.5A, 4.5B). Subsequently, Unc5b was down-regulated in 
HFD+SR group in compare to HFD+Vehcile group (Fig 4.5C). Systematic changes in 
Netrin-1 was assessed in serum of DIO mice either treated with SR141716A or vehicle as 
well as age-matched LFD group. The similar level of Netrin-1 was detected in all the 
groups (Supplementary Fig 4.2A). Netrin-1 concentration in supernatant of the cultured 
BMDM in conditioned media from differentiated 3T3-L1 cells to adipocytes, revealed 
that treatment with SR141716A significantly reduced the Netrin-1 level in compare to 
vehicle treated BMDM (Supplementary Fig 4.2B). Relative expression of the Netrin 
family and its corresponding was examined in LFD+Vehicle, HFD+Vehicle ,and 
HFD+SR groups ( Supplementary table 4.2) 
Herein, for the first time we revealed the molecular mechanistic effect of 
SR141716A on macrophage retention in adipose tissue via AGAP-2, a negative regulator 
of Unc5b, through altered profile of miRNA. Filtering the Ingenuity Systems IPA 
modules to the neuroimmune guidance cue canonical pathways, demonstrated the novel 
series of miR in targeting upstream negative regulator of Unc5b. Assessing the down-
stream effect of the interaction of AGAP-2 and altered miR following SR141716A 
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treatment in ATMs with MAP (Molecular Activation Predictor) module in IPA, revealed 
distinctive down-regulation of Unc5b in ATMs following SR141716A (Fig 4.5D). 
In order to validate the direct interaction of miR-762 and Unc5b, treated Bone 
Marrow Derived Macrophages (BMDM) with conditioned media from differentiated 
3T3-L1into adipocytes, were transfected with a plasmid with a Renilla luciferase 
(transfection efficiency control) and 3’UTR AGAP-2 of a Firefly luciferase reporter gene. 
Firefly luciferase expression is therefore; suppressed by the corresponding endogenous 
microRNA level in the cell. The day after the cell cultures were transfected with miR-762 
miRCURY LNA™ microRNA Inhibitor(5nM). Higher activity of the reporter gene 
demonstrated the direct interaction of AGAP-2 and miR-762 (Fig 4.5E) 
 
Interactions of SR141716A with Netrin-1 and UNC5B  
Results from molecular docking of SR141716A with Netrin-1 showed that 
SR141716A show polar interaction with the SER206 present in the Netrin-1 N-terminal 
domain VI (Fig 4.6B and 4.6C) with a binding energy of -7.13 kcal/mol and inhibition 
constant (Ki) of 5.94 µM. Further, results from molecular docking of SR141716A with 
Unc5b death domain showed that SR141716A has a polar interaction with the LEU927 
(Fig  4.6E, 4.6F and 4.6G) with a binding energy of -7.55 kcal/mol and Ki of 2.9 µM 
 
SR141716A inhibits macrophage retention in adipose tissue  
Recently it has been reported that over-secretion of netrin-1 from ATMs inhibits 
their egress from the adipose tissue and subsequently causes low-grade chronic 
inflammation which leads to metabolic dysfunction 274. Therefore; we hypothesized that 
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SR141716A inhibits ATMs retention in visceral adipose tissue by promoting macrophage 
emigration from the adipose tissue. To test this, we isolated peritoneal macrophages from 
thioglycolate stimulated mice, and cultured them in the presence of conditioned media 
from differentiated 3T3-L1 cells into adipocytes. The peritoneal macrophages were 
treated either with SR141716A or DMSO as a vehicle. Then after, their migration rate 
towards CCL19 was measured. CCL19 is the main chemokine which is implicated in 
emigration of tissue macrophages towards draining lymph node. Notably, SR141716A-
treated macrophages exhibit higher migration to CCL19 than DMSO-treated 
macrophages (Fig 4.7A), though the level expression of CCL19 receptor Ccr7 was 
equivalent in both groups (Fig 4.7B). According to these data, we postulated that 
SR141716 attenuates the over-secretion of Netrin-1 from ATMs in obese phenotype, and 
potentially promotes their emigration from adipose tissue, which leads to amendment of 
chronic inflammation in adipose tissue, and subsequently ameliorates the associated-
metabolic dysfunction.  
 
 
4.4 DISCUSSION 
In consistent with previous studies, our study confirmed the beneficial effect of 
cannabinoind CB1 receptor antagonist, specifically SR141716A, as an interventional 
treatment in obese phenotype 296,297,298,299. The transient reduction in calorie intake and 
sustained shrinkage of the fat mass, following SR141716A treatment, was demonstrated 
in our study and previous studies 295. Furthermore, previously we discovered the anti-
inflammatory effect of SR141716A treatment both systematically (serum) and locally 
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(colon, adipose tissue) in DIO phenotype. We revealed the beneficial effect of 
SR141716A on chronic inflammation and metabolic dysfunction in DIO phenotype, 
beyond its effect on restriction of calorie intake, by conducting the pair-feeding to 
SR141716A control. The clear link between between ATM retention, sustained chronic 
inflammation, and metabolic dysfunction within DIO phenotype has been well-
established 300-307. Herein, in continuation with our earlier study, we demonstrated the 
skew in ATMs population towards less pro-inflammatory M1 macrophages following 
SR141716A treatment in DIO phenotype.  
The direct molecular mechanism of SR141716A, in regulating the resolution of 
inflammation in adipose tissue remain elusive, but is likely to comprise reduced retention, 
efferocytosis and macrophage death, as well as alteration in ATMs polarization. Our 
results uncovered a key role for dysregulated miR in ATMs following SR141716A in 
mediating anti-inflammatory state in adipose tissue of DIO phenotype. Notably, we 
identified down-regulation of miR family, miR-466 following SR141716A treatment 
(HFD+SR) in compare to vehicle treated DIO mice (HFD+Vehicle). miR, negative 
regulators of gene expression, regulates 90% of gene function including different 
pathways. The main target genes of the miR-466 family are KLF4 and STAT6. Previous 
study revealed the key role of Krüppel-like factor 4 (KLF4) in regulating macrophage 
polarization 308,309. Furthermore, the loss of the function study of KLF4 in mice bearing 
myeloid-specific deletion of KLF4 (LysMCre/CreKlf4fl/fl, designated Mye-KO) 
exaggerated DIO phenotype and metabolic dysfunction (glucose intolerance and insulin 
resistance) 310. Interestingly, our data suggested that dysregulated family of miR-466 
following SR141716A treatment was involved in the cooperative interaction of KLF4 
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and STAT6 in polarization of M2 macrophages. The effect of SR141716A on miR-466 
family was beyond its effect on calorie intake.  
Furthermore, we identified the unique interaction between altered miR in 
HFD+SR group and molecules involved in neuroimmune guidance cue pathway. 
However; for the first time our data uncovered that therapeutic properties of SR141716A, 
in attenuation of adipose tissue inflammation, is implicated in targeting Netrin-1 and its 
receptor Unc5b in ATMs. Recent study demonstrated the novel role of neuroimmune 
guidancecue, Netrin-1 and its receptor Unc5b in regulating the chemotaxis behavior of 
ATMs 274. Indeed, less accumulation of ATMs in adipose tissue of HFD-fed Ntn1 -/- mice 
was identified in compare to HFD-fed wild type mice. The key regulatory role of Netrin-
1 in leukocytes transmigration into tissues (intestine, kidney ,and atherosclerosis plaques) 
was defined earlier 311,312,313. Indeed, abundant expression of Netrin-1 in residual 
macrophages of atherosclerotic plaques, exacerbate the disease state by attracting more 
macrophages to the site of inflammation 314. Additionally; higher expression of Netrin-1 
in endothelial cells of Apoe -/-  , and Ldlr -/- mice ameliorates atherosclerosis by inhibiting 
the leukocyte recruitment 315. Thus, conditional deletion of Netrin-1 and Unc5b in 
macrophages is desired to eliminate the off target effect of Netrin-1 deletion in other cells 
such as endothelial and epithelial. Outstandingly, SR141716A can be considered as an 
effective potential therapy in attenuation of chronic low-grade inflammation in adipose 
tissue, by targeting Netrin-1 and Unc5b exclusively in macrophages. Further 
investigation is required to identify and cover all the potential off targets of SR141716A 
therapy entirely. 
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Recently, the key functional role of Netrin-1 as the monocyte chemoattractant 
signals identified by monitoring the migration pattern of macrophages into and out of 
atherosclerotic plaques as well as adipose tissue of DIO phenotype 316,317. Utilizing the 
fluorescent microspheres monocyte labeling technique in HFD-fed Ntn1-/-  mice, 
demonstrated less retention of macrophages in adipose tissue and more emigration of 
them into drainage lymph node (Mesynteirc lymph node) 274. We demonstrated herein 
that cultured peritoneal macrophages in harvested medium from 3T3-L1 adipocytes, 
show higher migration to CCL19 in presence of SR141716A in compare to DMSO, 
despite equivalent expression of Ccr7 (CCL19 receptor). Therefore; we hypothesized that 
Netrin-1 in ATMs potentially was affected following SR141716A treatment, and 
subsequently leads to lesser frequency of macrophages in adipose tissue. 
 Although the implication of Netrin-1 in ATMs retention has been uncovered, but 
the underlying mechanism remain poorly defined. Herein, for the first time we identified 
the key role of AGAP-2, as the negative regulator of Unc5b in ATMs. Earlier the direct 
association of AGAP-2 and Unc5b in cancer cell line in a P53 dependent manner was 
identified 318. The over-expressed AGAP-2 fades Unc5b expression, inversely knocked 
down AGAP-2 intensifies Unc5b expression. Notably, you uncovered the role of miR-
762 in regulating AGAP-2 and the down-stream effect is ruling the association of Netrin-
1 and Unc5b in ATMs.  
Netrin-1 is an approximately 600 residue molecule (Uniprot ID: O09118) 
comprising of an N-terminal domain VI, three laminin-type epidermal growth factor (LE) 
repeats (V-1, V-2, and V-3) and a positively charged C-terminal domain 34(Figure 6a). 
Netrin-1 is known to show its activity through its main receptors Deleted in Colorectal 
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Carcinoma (DCC) and UNC5-homolog (UNC5H, i.e., UNC5A, UNC5B, UNC5C, 
UNC5D, or UNC5H1-H4) 319. These receptors upon binding to netrin-1 induce signals 
leading to the activation of MAPK or PI3K proteins 320,321 whereas unbound forms of 
these receptors trigger apoptosis 322,323. A previous study showed that the Ig1 domain of 
UNC5H2 is the primary interaction domain for the V-2 domain of netrin-1289. Our 
results, showed that SR141716A treatment has a significant change in the protein or 
mRNA levels of Netrin-1 and its receptor UNC5H2. Therefore, in order to check whether 
SR141716A has a role in blocking the Netrin-1 /UNC5H2 interaction by binding to the 
V-2 domain of netrin-1, we have performed molecular docking to search the entire 
surface of netrin-1 324. Results showed that SR141716A has polar interactions with the 
SER206 present in the Netrin-1 N-terminal domain VI (Figure 6c) indicating that 
SR141716A may not have a role in blocking the Netrin-1 /UNC5H2 interaction.  
UNC5B on the other hand, is a 604 residue molecule (Uniprot ID: Q8K1S3) 
comprising of a transmembrane region followed by ZU5, UPA and death domain 325. The 
complete three dimensional structure of UNC5B is not available and only the structure 
for death domain is available. Interaction analysis for SR141716A with netrin-1 showed 
that it is not interacting in the region of Netrin-1 /UNC5H2 interaction. Therefore, in 
order to predict the interacting residues on UNC5B with SR141716A we have performed 
docking to search the entire surface of UNC5B. Results showed that SR141716A has 
polar interactions with the LEU927 of the UNC5B death domain (Figure 6g). Further, 
these molecular docking analyses showed that UNC5B death domain has a lowest 
binding energy (-7.55 kcal/mol) indicating that it has a high binding affinity for 
SR141716A compared to Netrin-1 (-7.13 kcal/mol). The study provides an insight into 
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the role of SR141716A in the induction of activity for netrin-1, netrin-1 related receptors. 
However; further investigation is required for uncovering the potential effect of 
SR141716A on other neuronal immune guidance cue families such as Slit, Ephrin, 
Semaphorin and their related receptors in ATMs. 
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Figure 4.1 SR141716A ameliorates DIO phenotype by inducing weight loss. DIO 
mice were treated orally with either SR141716A (10mg/kg/day, HFD+SR) or Vehicle 
(.1% Tween 80) for 4 weeks and received HFD ad libitum. Pair-feeding to HFD+SR 
group was performed in PFSR group in order to consider the effect of SR141716A 
beyond its effect on diet intake. (A)Weekly body weight of each group of mice is shown 
during the whole period of treatment. (B)  Weekly energy intake during 4 weeks’ 
treatment with SR141716A in diet-induced obesity mice (C) average of daily diet intake 
for the period of stable diet intake (Day9-day28) (n=9-10).  Repeated data were analyzed 
using Generalized Estimating Equation (GEE) method in SPSS.  Groups were compared 
to the HFD+Vehicle control. Statistical significance was set with an alpha value of **p < 
0.01, #p < 0.05, ns (not significant).  
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Table 4.1 SR141716A causes significant shrinkage of fat mass. Body composition 
including fat mass, lean mass and fat percentage was assessed at baseline and after 4 
weeks of treatment using Dual Energy X-ray absorptiometry (DEXA).  Values are not 
sharing superscripted letters (a,b) differ significantly over time (p < 0.05). Values are not 
sharing superscripted symbols (#, @, &) differ significantly among different treated 
groups (p < 0.05).  
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Figure 4.2  SR141716A intervention treatment ameliorates metabolic dysfunction in 
DIO phenotype. Fasted metabolic parameters assessed at the baseline and prior to the 
sacrificing day (Day 27). (A) Fasting blood glucose (B) Insulin concentration (C) HOMA 
index =fasting insulin(µU/ml) x fasting glucose (mmol/l) /22.5 (D) Total cholesterol 
concentration  (E) Triglycerides concentration. Data were analyzed using one-way 
ANOVA, (n=9-10), significant differences from HFD+Vehicle group was demonstrated 
(#p < 0.05, ns (not significant)). 
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Figure 4.3  SR141716A treatment in DIO phenotype skew the ATMs balance to less 
Pro-inflammatory M1 and more Anti-inflammatory M2 macrophages. Changes in 
M1 and M2 expression in ATMs were assessed following SR141716A treatment in DIO 
mice. (A) RT-PCR from epididymal fat mass for iNOS and ARG-1. Data were analyzed 
using one-way ANOVA. Groups with different super-scripted letter or symbols are 
significantly different from each other (p < 0.05). (B) Differential expression heat map of 
3100 miRs between different treated group from F4/80 selected cells in adipose tissue (C) 
Cluster analysis of microRNAs showed that 36 miRs were up-regulated while 141 were 
down-regulated upon SR141716A administration compared to HFD+Vehicle group. Also 
164 were up-regulated while 25 were down-regulated compared to Pair-fed to 
SR141716A group. (D) Go enrichment mapping. miR target genes in HFD+SR were 
analyzed for GO enrichment and mapped for GO category: immune system process, 
using Cytoscape suite with ClueGo and CluePedia plugins. Two –sided hypergeometric 
statistic was performed with Kappa Score threshold setting of 0.3. Enrichment depletion 
were calculated based on Benjamini-Hochberg Correlated p values of <0.05. (E) 8. 
Interactions between the microRNAs and their target genes were assessed by Ingenuity 
Pathway Analysis (IPA) software.  SR141716A treatment changes the microRNA profile 
which skews the adipose tissue macrophage balance to more anti-inflammatory 
macrophages (M2, Arginase+) 
 Figure 4.3 
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Figure 4.4 miR-466 family targets M2 polarization in DIO was down-regulated 
following SR141716A, the effect is beyond of SR141716A effect on diet restriction.  
Isolated miRs from ATMs were filtered to exclusively altered miR following 
SR141716A treatment (A)Dual color bar graph of modified miRs due to the effect of 
SR141716A treatment beyond its effect on calorie restriction. (B) Correlation plot of 
Log2 fold change of (HFD+SR vs HFD+Vehicle) and Log2 fold changes of (HFD+SR vs 
PFSR) was conducted. Correlation R 2= 0.648 (univariate regression).(C) IPA analysis 
from filtered miRs revealed the family of miR-466 which is involved in M2 polarization 
in ATMs following SR141716A. 
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 Figure 4.4 
 
 
125 
Table 4.2 Summary of the unique miRs targets M2 polarization in ATMs, following 
SR141716A treatment in DIO phenotype. The applied algorithm, down-stream effect 
of altered miRs following SR141716A, target genes, and the log2 fold changes was 
summarized in Table 2. 
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Figure 4.5 SR141716A treatment changes the miR profile which modifies the 
adipose tissue macrophage retention via negative regulator of neuroimmune 
guidance cue, AGAP-2.  ATMs from different treated groups were examine for the 
changes in the level of nueroimmune guidance cue (A) Relative expression of Ntn-1 was 
assessed by RT-PCR and (B) western blot. (C) Relative expression of Unc5b was 
assessed by RT-PCR. (D) Interactions between the miR and their target genes were 
assessed by Ingenuity Pathway Analysis (IPA) software, filtered in neuroimmune 
guidance cue canonical pathway and MAP module was applied for down-stream effect 
prediction. (E) Bone Marrow Derived Macrophages (BMDM) were transfected with a 
plasmid with a Renilla luciferase (transfection efficiency control) and 3’UTR AGAP-2 of 
a Firefly luciferase reporter gene. Firefly luciferase expression is therefore suppressed by 
the corresponding endogenous microRNA level in the cell. The day after the cell cultures 
were transfected with miR-762 miRCURY LNA™ microRNA Inhibitor(5nM). Reporter 
gene expression was measured with a Dual Luciferase assay 24 hours after transfection. 
Data are shown as means ± SD. Statistical significance was set with an alpha value of *p 
< 0.05(student t-test) 
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Figure 4.6 Interactions of SR141716A with Netrin-1 and UNC5B. (A) shows the three 
dimensional structure of Netrin-1 with N-terminal domain VI (47-284) represented in 
orange, Laminin epidermal growth factor (EGF) like 1 (285-340) domain represented in 
green color, Laminin epidermal growth factor (EGF) like 2 (341-403) domain represented 
in yellow color , Laminin epidermal growth factor (EGF) like 3 (404-453) domain 
represented in magenta color and remaining regions were coloured in grey (B) Surface 
model of the docked Rimonabant with Netrin-1 where Netrin-1 is shown as surface and 
SR141716A is shown as sticks (C) Amino acid interactions of Netrin-1 N-terminal 
domain VI  (cartoon) and SR141716A (sticks) with polar contacts shown in yellow color 
dotted lines (D) shows the three dimensional structure of UNC5B death domain (854-
929) with helices represented in red and loops in green color (E) Surface model of the 
docked SR141716A with UNC5B where UNC5B is shown as surface and SR141716A is 
shown as cyan color sticks (F) shows the SR141716A interacting UNC5B with the 
binding pocket represented in green color mesh (G) Amino acid interactions of UNC5B 
death domain (cartoon) and SR141716A (sticks) with polar contacts shown in magenta 
color dotted lines. 
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Figure 4.7 SR141716A inhibits macrophage retention in adipose tissue. (A) 
Macrophage isolated from peritoneal wash of treated mice with 3%thyoglycolate. 
Isolated macrophages were stained in Dilc(12)3 and treated with SR141716A or Vehicle. 
Migration assay towards CCL19(500 ng/ml) was assessed by seeding 2.5*105  
macrophages in serum reduced conditioned medium from differentiated 3T3L-1 into 
adipocytes in  fluroblock plates. 12 hours later the migrated cells were quantified by 
Cytation5. (B)Real-time PCR was conducted for CCR7 receptor. SR141716A does not 
have any effect on the expression of CCR7 in macrophages. Data are shown as means ± 
SD. Statistical significance was set with an alpha value of **p < 0.01 (student t-test). 
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Supplementary figure 4.1 Down-regulated miR-466f and miR-466j* in DIO 
phenotype following SR141716A resulted in M2 polarization. ATMs were isolated 
from different treatment groups in our study. (A) RT-PCR for miR-466 family (B) RT-
PCR for KLF4 and STAT6 after in BMDM which were transfected with LNA power 
inhibitors for miR-466f and mir-466j*. Vertical bars represent mean ± SD Values with 
different superscript letters are significantly different, (P<0.01) according to post hoc 
ANOVA one-way statistical analysis. 
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Supplementary figure 4.2 SR141716A suppressed Netrin-1 secretion from BMDM. 
Systematic level of Netrin-1 was examined in serum of different study groups. (A) 
Netrin-1 concentration in serum. Vertical bars represent mean ± SD. According to post 
hoc ANOVA one-way statistical analysis, the differences between groups were not 
significant (B) Cultured BMDM in conditioned media from 3T3-L1 adipocytes were 
treated either with SR141716Aor DMSO (Vehicle). After 24 hours of treatment the 
supernatant were harvested for Netrin-1 Elisa. Vertical bars represent mean ± SD. Data 
were analyzed with Student t-test with ****p<.0001. 
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Supplementary Table 4.1 Primers sequences. The forward and reverse sequences of 
each primer used in the study.  
 
 
 
 
 
 
Supplementary Table 4.2 Neuronal guidance cue gene expression in HFD+Vehicle 
vs. LFD+Vehicle, and HFD+SR vs. HFD+Vehcile groups. The level expression of 
neuronal guidance cue and their receptors in epididymal fat mass of different group 
studies.  
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CHAPTER V: SUMMARY AND CONCLUSION 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), is an environmental contaminant 
and a potent ligand for AhR.  Recent studies suggested that AhR activation by TCDD 
induces the expression of Foxp3, a marker on Tregs responsible for immunosuppression.  
The precise mechanisms through which AhR activation up-regulates Foxp3 expression in 
T cells is not clear. 
In the current study, we investigated the role of microRNA (miR) and epigenetic 
markers in TCDD-induced expression of Foxp3 in T cells activated by Staphylococcal 
Enterotoxin B (SEB). We studied the effect of TCDD on purified Foxp3+Tregs from 
Foxp3/GFP knock-in mice injected with SEB, and treated with either vehicle or TCDD. 
Our studies showed that TCDD treatment decreased the percentage and numbers of SEB-
activated Vβ8+ T cells while promoting Foxp3+ Vβ8+ Tregs.  TCDD also suppressed 
pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-6) and induced anti-inflammatory 
cytokines (IL-10, and TGF-β). High throughput miR analysis followed by in silico 
analysis demonstrated that miRs induced by TCDD regulated several epigenetic 
pathways, that impacted the expression of Foxp3. 
Specifically, TCDD-mediated over-expression of miR-491 and miR-148a caused 
demethylation within the Foxp3 promoter region by targeting DNMT3a and DNMT3b.  
Moreover, reduction in DNMT3a and DNMT3b resulted in increased acetylation of 
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histone H3, which in turn led to promotion of the interaction with KLF10/SP-1, and 
consequent induction of Foxp3+. 
This was also supported by the findings that TCDD down-regulated the 
expression of miR-31 and miR-26b and consequently induced the expression of KLF10 
and SP-1, respectively.  Interestingly, miR-31, was found to be complementary to the 3’-
UTR of Foxp3 and CYP1A1 and induced the expression of these genes. Together, our 
studies demonstrate that AhR activation triggers miRs that cross-talk with multiple 
epigenetic pathways leading to the induction of Foxp3 and consequently, immune 
regulation. 
In the third and forth chapters, we investigated the chronic inflammation in diet-
induced obesity model. Obesity is characterized by chronic low-grade, systematic 
inflammation, altered gut microbiota and gut barrier disruption. The endocannabinoid 
system (eCB) plays a major role in the regulation of inflammation and metabolic 
disorders associated with obesity. In the current study, we investigated the effect of 
treatment of mice with SR141716A, a cannabinoid receptor1 (CB1) antagonist, on Diet 
Induced Obesity (DIO), specifically whether such a treatment can induce changes in gut 
microbiota and anti-inflammatory state in adipose tissue. 
Blockade of CB1 receptor reduced plasma LPS level, circulating inflammatory cytokines 
and the trafficking of M1 macrophages into the adipose tissue. This decreased 
inflammatory tone was associated with a lower intestinal permeability and improved 
hyperglycemia and insulin resistance. Analysis of fecal samples using 16S rRNA 
metagenomic sequencing to investigate alterations in the gut microbiome, revealed that 
treatment with SR141716A dramatically increased the relative abundance of 
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Akkermansia muciniphila within the Verrucomicrobia phylum. Drastic reduction in 
immunogenic Lanchnospiraceae and Erysipelotrichaceae with SR141716A treatment was 
beyond its effect on the weight loss and diet intake. High level of anti-inflammatory 
propionate and butyrate in cecal content of SR141716A treated group was also detected. 
Our data suggest that blocking of CB1 receptors ameliorates obesity by restoring gut 
microbiome and consequently their metabolites which modulate macrophage 
inflammatory mediators. 
Retention of Macrophages in adipose tissue is associated with high expression of 
neuroimmune guidance cue netrin-1 and its receptor UNC5B which are involved in 
chemotaxis. Suppression of pro-inflammatory macrophages was observed in 
SR141716A-treated HFD-fed group followed by down regulation of netrin-1 and UNC5B 
in macrophages. Molecular docking studies demonstrated interaction of SR141716A with 
both netrin-1 and UNC5B. Microarray and in silico analysis demonstrated that  miRs 
induced by SR141716A regulated several pathways including macrophage migration.  
Specifically, we uncovered that SR141716A treatment down-regulated miR-466 family 
that regulate transcription factors such as KLF4 and STAT6 leading to promotion of M2 
polarization.  Also, miR-762 which was down-regulated following SR141716A 
treatment, was found to be complementary to the 3’-UTR of AGAP-2 gene, a negative 
regulator of netrin-1 receptor, UNC5B.    
Thus, for the first time, we demonstrate that blockade of CB1 receptors leads to 
altered miR expression in adipose tissue macrophages that regulate netrin-1 and some key 
transcription factors leading to polarization to M2 macrophage phenotype and increased 
migration of such cells from adipose tissue leading to attenuation of obesity. 
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